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ABSTRACT 
 
Mechanisms of Deadenylation Regulation Under Different Cellular Conditions 
By 
Xiaokan Zhang 
 
 
Adviser: Professor  Frida Esther Kleiman 
 
Control of gene expression by regulating mRNA stability after DNA damage has 
the potential to contribute to the cells rapid response to stress. The main focus of this 
dissertation is to elucidate the role(s) of nuclear PARN deadenylase in controlling mRNA 
stability, hence gene expression, of factors in the p53 signaling pathway during the DNA 
damage response (DDR). Understanding the mechanisms of these regulatory pathways 
will provide new insights on how the control of gene expression upon DNA damage 
decides cellular fate, offering new opportunities for therapeutics. In Chapter II, I 
presented evidence that PARN along with the cleavage factor CstF-associated tumor 
suppressor BARD1 participates in the regulation of endogenous transcripts in different 
cellular conditions. In Chapter III, I identified the mRNA targets of PARN in non-stress 
conditions, and contributed to describing a feedback loop between p53 and PARN, in 
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which PARN deadenylase keeps p53 levels low by destabilizing p53 mRNA through its 
3′ untranslated region (3’UTR) in non-stress conditions, and the UV-induced increase in 
p53 activates PARN, regulating gene expression during DDR in a transactivation-
independent manner. In Chapter IV, I presented evidence that PARN deadenylase has a 
specific effect on the steady-state levels of not only AU-rich element-containing but also 
microRNA (miRNA)-regulated nuclear mRNAs. I showed that the functional interaction 
of PARN with miRNA-induced silencing complex contributes to p53 mRNA stability 
regulation. These studies provide the first description of PARN deadenylase function in 
miRNA-dependent control of mRNA decay and of miRNA-function in the nucleus. 
Finally, in Chapter V, I determine that nucleolin is one of the RNA binding proteins that 
recruits PARN to the p53 mRNA and this can be regulated by phosphorylation, 
representing a novel regulatory mechanism for p53 gene expression. The data presented 
in this dissertation has contributed to describe and comprehend some novel mechanisms 
behind the regulation of gene expression during DDR. 
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SIGNIFICANCE 
Cells are constantly exposed to stress caused by environmental factors such as 
oxidation, hydrolysis, alkylation, radiation and toxic chemicals. As a consequence, each 
cell in our body experiences more than 74,000 damages per day. If the damage is not 
repaired, DNA mutations might occur and proteins harmful to the cell might be 
expressed. The regulation of gene expression during the DNA damage response (DDR) is 
a fundamental cellular process that is controlled at multiple levels, such as transcription, 
mRNA processing and translation. While the study of gene expression regulation during 
DDR has been traditionally focused at the transcriptional level, it has recently become 
apparent that the role of post-transcriptional control may be equally important. 
The dynamic nature of the mRNA 3’-end processing machinery allows the 
regulation of the steady-state levels of different mRNAs and has the potential to 
contribute to the cells rapid response to stress. The DDR involves changes in mRNA 
steady-state levels and, consequently, in gene expression of different genes. For example, 
while the steady-state levels of genes involved in cell cycle and DNA repair change at 
different points of the response to allow DNA repair, the steady-state levels of most 
housekeeping genes are transiently decreased to avoid the formation of erroneously 
processed truncated mRNAs that might generate harmful proteins.  
mRNA polyadenylation and deadenylation are important processes that allow 
rapid regulation of gene expression in response to different cellular conditions. As the 
mRNA poly(A) tail is important in the regulation of mRNA steady-state levels, 
determination of how the poly(A) tail length of a particular mRNA and, consequently, its 
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stability are determined and regulated constitutes a major challenge in understanding 
control of gene expression in different cellular conditions. It has been established that 
modulation of the length of poly(A) tail of an mRNA by the 
polyadenylation/deadenylation machinery is a widespread strategy used to control mRNA 
stability and protein production in different cellular conditions such as development, 
mRNA surveillance, inflammatory response, cell differentiation, cancer, and especially 
during the DDR. One of the mechanisms underlying the transient decrease of cellular 
poly(A)
+
 mRNA levels after DNA damage involves the formation of a complex between 
the cleavage stimulation factor CstF, the deadenylation factor poly(A)-specific 
ribonuclease (PARN), and the tumor suppressors BARD1 (BRCA1-associated RING 
domain 1), BRCA1 and p53. The formation of BARD1/CstF1/PARN complex has a role 
in activating the deadenylase activity of PARN, while at the same time it inhibits the 3’ 
cleavage step of the polyadenylation reaction. PARN along with the CstF/BARD1 
complex participates in the regulation of the steady-state levels of endogenous transcripts 
under different cellular conditions. Any mutations or functional defects in those 
polyadenylation/deadenylation factors are prone to result in deregulation of proper gene 
expression, which may cause cancer.  
mRNA steady-state levels are regulated by microRNAs (miRNAs), AU-rich 
elements (ARE)-binding proteins (BP), polyadenylation/deadenylation factors, and RNA-
BP that recognize cis-acting sequences in the target mRNA. The dynamic change of these 
RNA-protein complexes regulates deadenylation signaling different checkpoints during 
DDR. The relevance of the functional connection between these cis-acting elements and 
the 3’ processing machinery is highlighted by changes in the length of the 3’UTR of 
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different mRNAs in cancer cells and during cell differentiation by the use of alternative 
3’ cleavage and polyadenylation signals (APA). Changes in the length of 3′UTRs of 
mRNAs can eliminate or include several cis-acting elements, such as miRNA target sites 
and AREs, and these changes can affect the stability, hence the abundance, of different 
transcript isoforms in different subtypes of tumors. The cis-acting elements are frequently 
present in genes that encode proteins involved in cell growth regulation, cell 
differentiation and DDR. Increasing evidence has been presented to show the important 
roles that ARE- and miRNA-mediated deadenylation plays in different biological 
processes. Interestingly, a functional overlapping in the regulation of mRNA stability by 
ARE- and miRNA-mediated regulatory pathways has also been described. The role of 
PARN deadenylase in these regulatory processes has not been elucidated.  
PARN has been shown to be involved in ARE-mediated deadenylation, and 
PARN expression has an effect on the steady-state levels of ARE-containing mRNAs, 
such as c-fos and c-myc, in non-stressed and UV-treated cells. In this thesis, I am 
investigating the role of cis-acting signals and trans-acting factors in regulating the 
stability of PARN target mRNAs.  The working model in this dissertation is that PARN 
deadenylase plays a role in nuclear mRNA degradation of one of its targets, the p53 
mRNA, through both ARE-mediated and miRNA-mediated regulatory pathways, and that 
miRNA-loaded miRISC contributes to the specific recruitment of nuclear PARN to its 
target mRNA in mammalian cells. In that scenario, I also investigated the role of 
nucleolin as one of the ARE-BPs involved in the recruitment of PARN deadenylase to its 
target mRNAs. The studies presented in this dissertation are highly significant at several 
levels. First, my studies were aimed at understanding control of gene expression by 
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regulation of mRNA stability during DDR, a field that remains largely unexplored. 
Second, my preliminary data provided first insights about the underlying molecular ties 
for such regulation. I identified that nucleolin, an RB protein that is highly expressed in 
cancers, interacts with PARN, an mRNA decay enzyme. Third, PARN has been 
extensively studied at the biochemical level but very little is known about its biological 
targets under different cellular conditions. Finally, I explored new regulatory mechanisms 
in the p53 pathway. While most of the studies on the expression of genes involved in 
stress response pathways have traditionally focused on transcription as a major regulator, 
it has recently become apparent that the posttranscriptional control of mRNA steady-state 
levels may play an equally important role. The mechanism(s) behind the regulation of 
p53 mRNA levels under non-stressed as well as DNA-damaging conditions has(ve) not 
been well characterized. My results indicate that PARN deadenylase keeps p53 levels 
low in non-stress conditions by interacting with both AREs and miRNA targeting sites in 
the 3’UTR and destabilizing the p53 mRNA. Importantly, these studies support the 
functional overlap between ARE- and miRNA-mediated mRNA turnover pathways, 
increasing the complexity of the signaling present in the 3’UTR of different genes. This 
is consistent with the idea that cell-specific 3′ processing profiles, and hence gene 
expression patterns, depends on the complexity of the signaling in the 3’UTR of the 
genes and the functional/dynamic interaction of the 3′ processing machinery and the 
DNA damage response/tumor suppression factors, providing functional connection 
between mRNA processing and cancer subtypes. The studies presented in this 
dissertation will serve as a valuable framework both for understanding these critical 
x 
 
biological processes and for developing appropriate therapeutic approaches to a variety of 
disorders, including cancer. 
Finally, evidence is presented in this dissertation of a novel regulatory miRNA-
mediated pathway in the nucleus. While most studies traditionally have focused on 
cytoplasmic miRNA-mediated pathways, miRNA’s nuclear functions have begun to 
emerge in recent years. Although miRNA-mediated gene silencing in the nucleus has 
been described, the mechanism(s) and deadenylase(s) involved in this process have not 
been elucidated. The data presented here is the first to address the mechanism behind 
miRNA-dependent control of deadenylation in the nucleus, showing the functional 
interplay among PARN deadenylase, the AREs in the 3’UTR, miRNA abundance and 
Ago-2 cellular localization. Together the studies presented here provide new insights of a 
regulatory pathway that involves a novel nuclear function of miRISC in mammalian cells 
as well as of the p53 pathway. 
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CHAPTER I 
BACKGROUND 
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NUCLEAR POLYADENYLATION/DEADENYLATION MACHINERIES 
Modulation of the length of poly(A) tail of an mRNA by the 
polyadenylation/deadenylation machinery is a widespread strategy used to control mRNA 
stability and gene expression in different cellular conditions, such as development, 
mRNA surveillance, inflammatory response, cell differentiation, cancer, and the DNA 
damage response (DDR). The dynamic nature of the mRNA 3’-end processing machinery 
allows the regulation of the steady-state levels of different mRNAs and has the potential 
to contribute to the cells rapid response to stress. Almost all eukaryotic mRNA precursors 
undergo a co-transcriptional cleavage followed by polyadenylation at the 3' end. After the 
signals are selected, polyadenylation occurs to full extent, suggesting that this first round 
of polyadenylation is a default modification for most mRNAs. However, the length of 
these poly(A) tails changes by the activation of deadenylation, which might regulate gene 
expression by affecting mRNA stability, mRNA transport or translation initiation . The 
mechanisms behind deadenylation activation are highly regulated and associated with 
different cellular conditions. After deadenylation, depending on the cellular response, 
some mRNAs might undergo an extension of the poly(A) tail or degradation. The 
polyadenylation/deadenylation machinery itself, microRNAs (miRNAs) or RNA binding 
factors are involved in the regulation of polyadenylation/deadenylation. Studies on the 
interplay between polyadenylation and deadenylation are providing critical information 
required for a mechanistic understanding of several diseases, including cancer 
development. 
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Figure 1. Schematic representation of the mammalian mRNA 3’ end 
formation. The cleavage step of the 3’ end processing is initialed by the assembly 
of cleavage complex through a cooperative binding of CstF at the G/U- and U-
rich region and CPSF at the AAUAAA signal. CPSF-160 directly interacts with 
CstF3 (77kD) and PAP. CF I, CF II and RNAP II also play a role in the cleavage 
reaction. After the cleavage step, CPSF and PAP remain bound to the cleaved 
RNA and elongate a 200-adenosine residue poly(A) tail to the 3’end of the 
cleaved product in the presence of PABP.  Taken from Zhao et al. (1999)  
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Almost all eukaryotic mRNA precursors, with the exception of histones, undergo 
a co-transcriptional modification at the 3' end. The 3’ end formation includes a two-step 
reaction, an initial cleavage step followed by the synthesis of a 200-adenosine residue tail 
to the 3’ end of the upstream cleavage product (Figure 1; reviewed in (Zhao et al., 1999) 
(Shatkin and Manley, 2000; Shi et al., 2009). In mammalian cells, the poly(A) tail length 
is approximately 200-250 nucleotides long (Brawerman, 1981; Wahle and Winkler, 
2013). Polyadenylation plays a fundamental role in regulating mRNA stability, 
translation and nuclear export, and thus is essential for the proper control of mRNA 
levels and of gene expression in eukaryotes (Colgan and Manley, 1997; Zhao et al., 
1999). It has been shown that regulation of 3’ end formation plays crucial role in cell 
growth control (Chuvpilo et al., 1999; D'Ambrogio et al., 2013; Takagaki and Manley, 
1998; Takagaki et al., 1996) and perhaps in diseases, especially in tumor cells (Scorilas, 
2002). One of the first steps of the reaction is the recognition of the highly conserved 
hexamer AAUAAA located at 10 to 30 nucleotides upstream of the cleavage site by the 
cleavage and polyadenylation specific factor (CPSF) and of the G/U- and U-rich region 
located further downstream by cleavage stimulation factor (CstF(Takagaki and Manley, 
1997). While a relatively simple signal sequence in the precursor mRNA is required for 
the reaction, many diverse and specific interactions between a large number of protein 
factors are involved in the formation of polyadenylation complex and regulation of 3’ end 
processing in different tissues and in different cellular conditions. While CPSF, CstF, 
cleavage factors 1 and 2 (CF I and CF II, respectively), RNA polymerase II (RNAP II) 
and poly(A) polymerase (PAP) play a role in the endonucleolytic cleavage step and help 
to specify the site of processing; CPSF, PAP, symplekin and poly(A) binding protein 
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(PABP) are involved in the polyadenylation step. CstF is one of the essential 
polyadenylation factors. CstF is active most likely as a dimer with each subunit 
consisting of three protein factors called CstF1 (55 kDa), CstF2 (64 kDa) and CstF3 (77 
kDa). CstF2 is largely responsible for RNA binding (Takagaki and Manley, 1997). Both 
CstF1 and CstF3 subunits interact with the C-terminal domain (CTD) of the largest 
subunit RNAP II LS, likely facilitating the RNAP II- mediated activation of 3’-end 
processing and linking transcription and RNA processing (Hirose and Manley, 1998; 
McCracken et al., 1997; Mirkin et al., 2008). CstF1 plays important roles in regulation of 
mRNA processing by interacting with other factors (Figure 2). It contains seven WD-40 
(tryptophan-aspartic acid) repeats, which are characteristic of regulatory proteins 
involved in protein-protein interactions (Neer et al., 1994; Takagaki and Manley, 1992), 
and an N-terminal hydrophobic region.  
All organisms are constantly exposed to a variety of environment agents that 
damage the DNA, such as UV-light, ionizing radiation and chemicals, which may lead to 
 
 
 
 
Figure 2. The 3’ processing factor CstF1. The CstF1 subunit of the CstF 
complex contains seven WD-40 (tryptophan-aspartic acid) repeats and an N-
terminal hydrophobic region.  
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replication and transcription blockages, mutagenesis, and cellular cytotoxicity (Friedberg, 
1995; Wood, 1996).
 
The maintenance of genome integrity and fidelity is essential for the 
proper function and survival of all cells, and requires the coordinated control of gene 
expression and DNA repair mechanisms to recognize and correct DNA lesions (Lindahl, 
1993; Sancar, 1994). One example is provided by the transient decrease of cellular 
poly(A)
+ 
mRNA levels following UV-irradiation and its normal recovery as part of the 
DDR (Hanawalt, 1994; Ljungman, 1999). Although the mechanism involved in this 
response is still not clear, it has been suggested that the decrease of mRNA level is due to 
UV-induced transcription inhibition (Donahue et al., 1996).
 
This indeed is likely a 
significant part of the mechanism. However, those studies have not considered the 
important role of RNA processing on mRNA levels. Consistent with this, following UV-
irradiation, the 3’ cleavage step of the polyadenylation reaction is repressed as a result of 
the direct interaction between the polyadenylation factor CstF1 with the tumor suppressor 
factor BARD1 (Kleiman and Manley, 1999). The UV-induced inhibition of mRNA 3’ 
processing occurs in a similar time frame that the UV-induced decrease of poly(A)
+
 
mRNA levels.  BARD1 is a 97 kDa nuclear protein that associates with the breast cancer 
susceptibility gene product BRCA1 (Wu et al., 1996). Both proteins share structural 
features, they possess N-terminal RING finger motifs, which are responsible for the 
BRCA1/BARD1 interaction, three ankyrin repeats that are involved in protein-protein 
interactions, and two BRCA1 C-terminal (BRCT) domains that are involved in DNA 
repair and cell cycle regulation.
 
BRCA1/BARD1 stabilizes each other and their 
association enhances their functions (Baer and Ludwig, 2002). It has been shown that the 
DNA-damage induced inhibition of polyadenylation correlates with increasing amount of 
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a BRCA1/BARD1/CstF complex formation (Kleiman and Manley, 2001), providing a 
link between transcription-coupled RNA processing and DNA repair. Moreover, mRNA 
3’ end processing can also be repressed following DNA damage as a result of the 
proteasome-mediated degradation of RNAP II, representing another possible redundant, 
mechanism to explain the UV-induced inhibition of 3’ processing (Kleiman et al., 2005).   
Interestingly, the mechanism underlying the regulation of 3’ end cleavage in 
response to DNA damage also involves the functional interaction of the deadenylation/ 
polyadenylation machineries. As discussed in Chapter II, my studies have shown that 
following UV-induced DNA damage, the polyadenylation factor CstF1 directly interacts 
with the deadenylation factor poly(A)-specific ribonuclease (PARN) inhibiting the 3’ 
cleavage step of polyadenylation and activating deadenylation in the nucleus, suggesting 
the existence of alternative mechanisms to regulate gene expression under different 
cellular conditions (Cevher et al., 2010).  Although most of the polyadenylation factors 
have been described and the reaction is now relatively well understood, the mechanisms 
underlying poly(A) removal are much less defined. In mammalian cells, the removal of 
the mRNA poly(A) tail is the earliest and rate-limiting step in mRNA decay (Chen and 
Shyu, 2003; Wilusz et al., 2001). Several mRNA decay pathways have been studied in 
eukaryotic cell, most of which are deadenylation dependent (Parker and Song, 2004). 
Two major PARN-mediated pathways of mRNA degradation have been defined: the 3’-
5’ decay pathway and the deadenylation-dependent decapping pathway (Figure 3; 
(Beelman and Parker, 1995; von der Haar et al., 2004). In the 3’-5’ decay pathway the 
degradation occurs in the cytoplasmic exosome in the 3’-5’ direction after the removal of 
the poly(A) tail, while in the deadenylation-dependent decapping pathway degradation is 
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initiated by deadenylation followed by DCP1:DCP2- mediated decapping and 5’-3’ 
exonucleolytic degradation of mRNA by the Xrn1p 5’ exonuclease (Caponigro and 
Parker, 1996; Mukherjee et al., 2002). In addition to these general mRNA decay 
pathways, other degradation pathways exist. For example, another well-known mRNA 
decay pathway is nonsense mediated mRNA decay (NMD). NMD is a quality control 
mechanism which  
 
   
 
 
 
 
 
Figure 3. PARN-mediated degradation of mRNA in the cytoplasm. Two major 
PARN-mediated pathways of mRNA degradation have been defined: 1) After the 
removal of the poly(A) tail, mRNA is first decapped by DCP followed by 
exonuclease XRN1-dependent degradation in the 5’3’ direction. 2) After 
deadenylation, mRNA degradation occurs in the 3’5’ direction by the exosome 
followed by decapping of the 5’ end.  Modified from Dr. Wilusz lab webpage 
http://www.cvmbs.colostate.edu/mip/wiluszlab/whatwedo.html   
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selectively eliminates mRNAs harboring premature termination codons (Karam et al., 
2013; Li and Wilkinson, 1998; Maquat, 1995). NMD is believed to occur not only in the 
cytoplasm but also in the nucleus since some ribosomal and translational activities have 
been detected in that compartment (Ishigaki et al., 2001; Trcek et al., 2013). Interestingly, 
PARN copurifies with essential NMD factors and PARN down-regulation abrogated 
nonsense-mediated decay (Lejeune et al., 2003).   
The steady-state levels of cellular mRNAs are determined by the balance between 
their biosynthesis and turnover. Different mRNAs within the same cell have distinct 
lifetimes. In mammalian cells, mRNA lifetimes range from several minutes to days, 
depending on various genes and the cellular conditions (Khodursky and Bernstein, 2003). 
The mechanisms controlling deadenylation are dynamic and highly regulated.  
Deadenylation processes are a widespread strategy that allows rapid control of mRNA 
stability, and represent additional checkpoint targets in the regulation of gene expression. 
Deadenylases are the key catalytic exoribonucleases that are required for proper 
regulation of poly(A) tail length by degrading poly(A) tail in a 3’ to 5’ direction. In 
mammalian cells, a number of deadenylases have been identified and studied in detail. 
There are two superfamilies of deadenylases: DEDD (Asp-Glu-Asp-Asp)-type enzyme, 
and EEP (endonuclease-exonuclease-phosphatase)-type deadenylase (Goldstrohm and 
Wickens, 2008). All known deadenylases belong to either superfamilies, for example, 
POP2, PARN, poly(A) nuclease (PAN2) and CAF1 deadenylase belong to DEDD 
superfamily, while CCR4 and Nocturnin deadenyase belong to EEP superfamily 
(Goldstrohm and Wickens, 2008; Thore et al., 2003; Zuo and Deutscher, 2001). 
Interestingly, some multi-subunit deadenylases are composed from subunits from both 
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families (Doidge et al., 2012). It has been shown that deadenylases localize both in the 
nucleus and the cytoplasm and are involved in different cellular processes. The best 
characterized deadenylases so far are the CCR4-POP2-NOT multi-subunit complex, 
which is the predominant deadenylase in eukaryotes, PARN, a divalent metal-ion 
dependent, processive and cap-interacting exoribonuclease, and (PAN), which is involved 
in early steps of poly(A) tail metabolism.  
PARN is one of the three major poly(A) specific 3’ exoribonucleases identified in 
mammalian cells (Mitchell and Tollervey, 2000; Wu et al., 2005).
 
PARN is expressed 
ubiquitously in all tissues of most eukaryotic organisms (Copeland and Wormington, 
2001). In calf thymus cell free extracts and in Xenopus oocytes two isoforms of PARN 
have been described with molecular sizes of approximately 74 kDa and 62 kDa, both of 
which have shown enzymatic activity and different nuclear-cytoplasmic distribution. 
While the 74 kDa isoform of PARN is exclusively nuclear, the 62 kDa isoform is 
cytoplasmic (Korner et al., 1998; Martinez et al., 2000).
 
So far, it has remained obscure 
how the subcellular localization of PARN is regulated, although it appears likely that 
proteolytic cleavage plays a role. While the cytoplasmic PARN’s activity has been 
extensively studied, the nuclear functions of PARN are not completely understood. 
PARN is found mostly in the nucleus and it does not seem tk play a key role in 
cytoplasmic mRNA decay (Ota et al., 2011). PARN has been identified as an oligomeric, 
highly processive, metal-ion dependent and cap-interacting poly(A) specific 3’ 
exonuclease (Grishin, 1998). PARN consists of a nuclease domain that performs the 
deadenylation reaction, a R3H domain, which is constituted by an invariant arginine that 
is separated by three residues from a highly conserved histidine and binds single stranded 
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nucleotides, and a RNA recognition motif (RRM) (Figure 4; (Wu et al., 2005).  While the 
R3H domain is responsible for PARN’s specificity for single-stranded poly(A) (Martinez 
et al., 2001), the RRM harbors the cap binding properties (Nilsson et al., 2007). It also 
has been shown that its deadenylation activity and processivity is enhanced by the mRNA 
5’-end-located cap structure (Astrom et al., 1992; Dehlin et al., 2000; Korner et al., 1998; 
Martinez et al., 2001).
 
On the other hand, PARN activity is inhibited by cap binding 
protein (CBP80) or nuclear poly(A) binding protein-1 (PABPN-1) (Balatsos et al., 2006; 
Gao et al., 2001). It has been suggested that PARN simultaneous interaction with the cap 
structure and the 3’ end located poly(A) tail shields the 5’ from decapping enzymes and 
initiates the deadenylation process. Interestingly, the communication between both the 3’ 
and 5’ ends of mRNA is very important because it integrates the initiation of translation, 
translation and mRNA turnover (Martinez et al., 2001).  
 
 
 
 
Figure 4. PARN consists of a nuclease domain, a R3H domain, and a RRM 
motif. R3H domain, a single-stranded nucleic-acid-binding domain, is responsible 
for PARN’s specificity for single-stranded poly(A), while the RRM harbors the 
cap binding properties. Modified from He et al. (2013).  
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Besides, PARN can promote deadenylation of AU-rich elements (AREs)-
containing mRNAs in the presence of tristetraprolin (TTP; (Lai et al., 2003). 
Interestingly, it has been described that UV induces stabilization of ARE-containing 
mRNAS; such as c-fos, kin17, c-jun, IB and c-myc (Blattner et al., 2000). It has also 
been shown that the UV-induced transcript stabilization and enhanced protein levels of 
short basal half–life, such as oncogenes, apoptosis and cell-cycle related genes, growth 
factors and cytokines, is due to the inhibition of cytoplasmic mRNA deadenylation and 
degradation (Gowrishankar et al., 2005).  
 
AU RICH ELEMENT MEDIATED DEADENYLATION 
About 54% of human genes have more than one conserved polyadenylation sites 
that show different efficiencies of polyadenylation (Tian et al., 2005). Several cis-acting 
elements within the 3’ untranslated region (3’UTRs) are responsible for the selection 
among these alternative polyadenylation (APA) sites. Although a direct connection 
between APA and the polyadenylation/deadenylation machinery has not been described, 
the selection between the distal or proximal alternative signals might cause the inclusion 
or exclusion of other cis-acting RNA elements which are involved in 
polyadenylation/deadenylation processes (Figure 5). The relevance of these regulatory 
processes is highlighted by the finding that changes in the length of the 3’ UTRs of 
different mRNAs due to alternative 3’ cleavage and polyadenylation changes the number 
of miRNA target sites and AREs in cancer cells (Mayr and Bartel, 2009; Shi, 2012; Singh 
et al., 2009), and during cell differentiation (Ji et al., 2009; Sandberg et al., 2008; 
Zlotorynski and Agami, 2008). Interestingly, deadenylation is often under the control of 
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cis-acting regulatory elements, which includes AREs and miRNA target sites, within the 
3’UTRs of eukaryotic mRNAs. 
About 12% of mammalian mRNAs bear an important regulatory signal known as 
AREs in their 3’UTRs, which has been shown to play significant roles in mRNA stability 
regulation (Guhaniyogi and Brewer, 2001). The ARE typically contains one or several 
AUUUA pentamer repeats within a U-rich region of the 3’UTR (Chen and Shyu, 1995; 
Lagnado et al., 1994; Zubiaga et al., 1995). ARE sequences are frequently present in 
genes that encode tightly regulated proteins involved in cell growth regulation, cell  
differentiation and responses to external stimuli. The destabilizing functions of AREs are 
 
 
Figure 5. Schematic diagrams of cis-acting RNA sequences at the 3'UTR 
involved in polyadenylation/deadenylation processes. The selection between 
the proximal or distal alternative polyadenylation signals leads to the exclusion or 
inclusion of cis-acting RNA sequences, such as miRNA target sites and ARE, 
which might mediate polyadenylation/deadenylation processes. Taken from 
Zhang et al., (2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 
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2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 
2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 2010)(Zhang et al., 
2010)  
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important because in their absence proto-oncogenes, such as c-fos, c-myc and c-jun, 
could become oncogenes (Schiavi et al., 1992).  
A number of trans-acting factors, known as ARE-binding proteins (ARE-BPs), 
regulate ARE-mediated decay and, subsequently, modulate the stability of ARE-
containing mRNAs. ARE-BPs either recruit deadenylases to the target mRNAs 
promoting deadenylation or block the recruitment of deadenylases and exosome 
inhibiting deadenylation. The ARE-BPs that promote ARE-containing mRNAs decay 
include tristetraprolin (TTP), butyrate response factor 1 (BRF1), AU-rich binding factor 1 
(AUF1) and KH-type splicing regulatory protein (KHSRP or KSRP); only Hu protein R 
(HuR) has been shown to play a role in stabilizing ARE-containing mRNAs (Barreau et 
al., 2005; Fan and Steitz, 1998; Ma et al., 1996; Westmark et al., 2005). For example, 
TTP directs its target ARE-containing mRNA tumor necrosis factor (TNF-α) for 
degradation by expediting removal of the poly(A) tail. Interestingly, the phosphorylation 
of TTP inhibits the recruitment of CAF1 deadenylase, and as a result, it reduces the 
ability of TTP to promote deadenylation (Dean et al., 2004; Lai et al., 1999; Marchese et 
al., 2010; Winzen et al., 2004). Supporting the idea that CAF1-CCR4-NOT deadenylase 
complex plays a critical role in ARE-mediated deadenylation, knockdown of CAF1 has 
been shown to abrogate deadenylation and decay of the ARE-containing α-globin mRNA 
(Schwede et al., 2008; Zheng et al., 2008). Interestingly, PARN deadenylase has also 
been shown to be involved in ARE-mediated deadenylation: KSRP recruits PARN to 
ARE-containing mRNAs to initiate the poly(A) tail shortening that precedes degradation 
by the exosome (Gherzi et al., 2004). PARN could also promote TTP-directed   
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Figure 6. Model of ARE -mediated regulation of deadenylation. The ARE -
binding proteins mediate destabilization and/or stabilization of the ARE -
containing mRNAs. ARE-BPs, such as AUF1, TTP, BRF1 and KHSRP, recruit 
deadenylases, such as PARN and CAF1-CCR4-NOT, to target ARE-containing 
mRNAs and initiate the deadenylation process that precedes degradation. Another 
ARE -BP, HuR, plays a role in stabilizing ARE -containing mRNAs by blocking 
the binding of ARE-BPs involved in the destabilization of ARE -mRNAs, such as 
AUF1, TTP and KHSRP. This competition stabilizes the association of PABP to 
the poly(A) tail or prevents the recruitment of deadenylases to the ARE -mRNA. 
Taken from Zhang et al., (2010)  
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deadenylation in vitro (Korner et al., 1998; Lai et al., 2003; Lin et al., 2007; Moraes et 
al., 2006). As discussed in Chapters II and III, my recent studies also indicated that 
PARN deadenylase has a role regulating the stabilities of ARE-containing mRNAs, such 
as c-fos and c-myc, in non-stressed cells (Cevher and Kleiman, 2010; Devany et al., 
2013).  
Nucleolin is a multifunctional ARE-BP with multiple subcellular localizations in 
the cell. Nucleolin is localized ubiquitously in the nucleolus, and is also found in other 
nuclear regions, as well as in the cytoplasm and the plasma membrane (Borer et al., 1989; 
Ginisty et al., 1999). Nucleolin protein contains multiple phosphorylation sites in its 
acidic N-terminal region, four RNA-binding domains mediating the interaction with 
mRNAs and pre-rRNA in the central region, and arginine/glycine-rich domain 
(RGG/GAR) in the C-terminal region, which can also interact with target mRNAs as well 
as with other proteins (Figure 7; Ghisolfi et al., 1992; Serin et al., 1996; Bouvet et al., 
1998; (Abdelmohsen et al., 2011; Bouvet et al., 1998; Ghisolfi et al., 1992; Serin et al., 
1996). Phosphoprotein nucleolin could be phosphorylated by numerous kinases, such as 
Cdc2, casein kinase II (CKII), protein kinase C (PKC) and the stress activated protein 
kinase p38 (Dranovsky et al., 2001; Tediose et al., 2010; Yang et al., 2002; Zhou et al., 
1997). The role of most of these phosphorylation events is not well understood. Nucleolin 
has been implicated in many different cellular processes, such as chromatin remodeling 
(Angelov et al., 2006), ribosomal RNA (rRNA) processing (Ginisty et al., 1998), 
ribosome assembly (Turner et al., 2009) and nucleo-cytoplasmic transport (Hovanessian 
et al., 2010). Besides, nucleolin participates extensively in the post-transcriptional fate 
control of mRNA targets, which typically contain AREs in their 3’UTR. 
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Nucleolin modulates the stability and translation of target mRNAs through 
multiple ways. First, nucleolin affects mRNA turnover, both increasing and decreasing 
mRNA half-life, by interacting with the 5’UTR and/or 3’UTR of target mRNAs. For 
example, in leukemia cells, nucleolin enhances the expression of pro-oncogenic protein 
B-cell lymphoma 2 (Bcl-2), which blocks apoptosis in cancer cells (Yang et al., 1997), by 
stabilizing BCL2 mRNA through the association with its ARE at 3’UTR (Sengupta et al., 
2004). Another mRNA target of nucleolin is the amyloid precursor protein (APP), which 
is linked to Alzheimer’s disease. Nucleolin associates with the 3’UTR of APP mRNA, 
and accelerates its degradation in response to stress (Westmark and Malter, 2001). 
Nucleolin also has influence on the translation of a subset of associated mRNAs. 
 
 
 
Figure 7. Schematics of nucleolin domains: The acidic N-terminal region of 
nucleolin protein contains multiple phosphorylation sites; the central region 
contains four RNA-binding domains, which are responsible for the interaction with 
mRNAs and pre-rRNA; and arginine/glycine-rich domain (RGG/GAR) in the C-
terminal region can also interact with target mRNAs and protein factors. Taken 
from Bhatt et al., (2012)   
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Nucleolin has been found to bind to p53 mRNA and suppressed its translation 
(Takagi et al., 2005). Interestingly, nucleolin is highly expressed in proliferating cells, 
such as cancer and stem cells. Nucleolin’s ability to associate with mRNA of target 
genes, which are functionally involved in stress response, cell survival, as well as cancer, 
and regulate their expression through changes of either mRNA stability or translation 
efficiency, might explain its implication in human disease. Recently, nucleolin has also 
been reported to play a role in the regulation of the biogenesis of tumorigenic 
microRNAs, such as miR-15a and miR-16 (Pickering et al., 2011), suggesting new roles 
for nucleolin in controlling gene expression.  
 
miRNA MEDIATED DEADENYLATION 
miRNAs comprise a large family of small single-stranded non-coding RNAs 
(~21nt in length), which are encoded within the genome of species ranging from 
protozoans to plants to mammals. miRNAs play key roles in a broad range of biological 
processes. In mammals, it is predicted that the regulation of more than 60% of all protein-
coding genes are mediated by miRNAs. They act at the post-transcriptional level to 
modulate gene expression, by imperfectly base-pairing to the target mRNAs. In most 
studied animals’ miRNAs, the hybrids are formed between the miRNA 5’- proximal 
“seed” region and the complementary sequences in the 3’UTRs of the target mRNA 
(Bushati and Cohen, 2007; Filipowicz et al., 2008; Friedman et al., 2009; Ghildiyal and 
Zamore, 2009; Mayr and Bartel, 2009). It has been shown that each mRNA could be 
regulated by more than one miRNA, and each miRNA could base-pair with more than 
one target mRNAs.  
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While most studies traditionally have focused on cytoplasmic miRNA-mediated 
pathways, miRNA’s nuclear functions have begun to emerge in recent years. Although 
miRNA-mediated gene silencing in the nucleus has been described (Nishi et al., 2013; 
Robb et al., 2005), the mechanism(s) and deadenylase(s) involved in this process have 
not been elucidated. Generally, miRNAs inhibit protein synthesis either through 
translation repression and/or through deadenylation activation, which leads to mRNA 
degradation (Chekulaeva and Filipowicz, 2009; Eulalio et al., 2008; Filipowicz et al., 
2008). These two mechanisms have been identified as two distinct independent pathways: 
the ability of miRNAs to expedite deadenylation does not depend on decreased 
translation; nor does translational repression by miRNAs require a poly(A) tail (Wu et al., 
2006).
 
Recently, it is also reported that some miRNAs could also function as translation 
activator in specific situations (Henke et al., 2008; Orom et al., 2008; Vasudevan et al., 
2008). miRNAs function in the form of ribonucleoprotein complexes, known as miRNA-
induced silencing complex (miRISC), which deliver miRNAs to their mRNA targets. 
Argonaute (Ago) and GW182 family proteins are the best-characterized protein 
components involved in the miRNA-mediated gene expression control (Chekulaeva and 
Filipowicz, 2009; Eulalio et al., 2008).
 
The key components of miRISCs are Ago family proteins. Ago proteins contain 
three evolutionarily conserved domains, PAZ, MID and PIWI. Through these domains, 
Ago proteins are able to associate with 3’ and 5’ end of the miRNA (Jinek and Doudna, 
2009; Peters and Meister, 2007). In mammals, four Ago proteins, Ago1 through Ago4, 
function in miRNA induced translation repression. Interestingly, Ago proteins are able to 
repress protein synthesis when artificially tethered to the mRNA 3’UTR (Pillai et al., 
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2004; Pillai et al., 2005; Wu et al., 2008), indicating that their involvement in control of 
mRNA expression is miRNA-independent. It has been shown that some Ago proteins are 
more potent repressors than others and cell- and tissue-specificity has also been reported 
in some studies (Wu et al., 2008). It has also been described that knockdown of Ago2 in 
human HEK293 cells lead to a much more profound effect on miRNA-mediated 
repression than the knockdown of the other three Ago proteins, suggesting that in 
mammals Ago2 may have some specific functions that other Ago proteins cannot 
complement (Schmitter et al., 2006). GW182 proteins are another group of factors crucial 
for miRNA-mediated functions (Eulalio et al., 2009). There are three mammalian GW182 
proteins, known as TNRC6A, -B and –C. They interact directly with Agos through their 
GW repeats located in the N-terminal portion of the protein, and act downstream of Agos 
(Eulalio et al., 2009; Till et al., 2007). It has been shown that the disruption of GW182-
Ago interaction by point mutations or peptide competition results in abrogation of 
miRNA-mediated repression, indicating the crucial role of GW182-Ago interaction 
(Eulalio et al., 2009; Till et al., 2007)). 
 
Additional protein components of miRISCs have 
also been identified to function as regulators in miRNA-mediated repression (Peters and 
Meister, 2007). 
Much evidence supports the idea that miRNAs destabilize target mRNAs through 
deadenylation and subsequent decay (Figure 8). Many studies have showed that the levels 
of specific miRNAs, or the activity of the miRNA machinery, have profound effect on 
the level of miRNA-targets and that the miRNA-mediated downregulation of the levels of 
target mRNA has important biological consequences  (Johnson et al., 2005; Sampson et 
al., 2007; Wakiyama et al., 2007). The deadenylation and the subsequent decay of 
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mRNAs targeted by miRNAs require the Ago and GW182 components of the miRISC 
(Akao et al., 2006; Lazzaretti et al., 2009).
 
The knockdown of human Ago2 abrogates 
miRNA-mediated deadenylation; while the disruption of GW182-Ago interaction also 
fails to activate mRNA deadenylation (Eulalio et al., 2008; Till et al., 2007). The 
cytoplasmic poly(A) binding protein 1 (PABPC-1) is an additional protein component 
that is critical for the miRNA-mediated deadenylation. It has been shown that a 
conserved motif in GW182 interacts with the C-terminal domain of PABPC-1 and that 
this interaction and the activity of PABPC-1 contribute to miRNA-mediated poly(A) 
removal  (Fabian et al., 2009; Jinek et al., 2010; Zekri et al., 2009).
 
It has been proposed 
that the miRNA-mediated degradation of mRNAs involves the association of Ago 
 
 
 
 
 
 
Figure 8. Model of miRNA-mediated deadenylation. miRISCs, which contain 
Ago, GW182, PABPC1 and either CAF1-CCR4-NOT (as indicated) or Pan2-
Pan3 (not shown) deadenylases, deliver miRNAs to the target mRNAs and 
mediate deadenylation, which leads subsequently to mRNA degradation. Taken 
from Zhang et al., (2010)  
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proteins to the miRNAs and the recruitment of GW182 to the target mRNAs via its N-
terminal domain; then the GW182 C-terminal silencing domain recruits the deadenylase 
complex through the interaction with PABPC-1 (Goss and Kleiman, 2013). One of the 
most studied deadenylases involved in miRISCs is the CAF1-CCR4-NOT1 complex, 
which contains two protein factors with deadenylase activity, CCR4 and CAF1. It has 
been shown that the CAF1-CCR4-NOT complex associates with PABPC-1, and the 
deadenylase activity of the CAF1-CCR4-NOT complex is necessary for  the miRNA-
mediated degradation (Zekri et al., 2009). Supporting these results, both the knockdown 
of CAF1 or NOT1 expression
 
and the over-expression of CCR4 or CAF1 mutants 
significantly reduce miRNA-mediated deadenylation and mRNA decay, but not 
translational repression (Behm-Ansmant et al., 2006; Fabian et al., 2009; Piao et al., 
2010).
 
Although the miRISC has been shown to functionally interact with several 
deadenylases, its functional interaction with PARN has not been elucidated.  
Interestingly, some of the seed signals recognized by miRNA overlap with AREs in the 
3’UTR (Bhattacharyya et al., 2006; Jing et al., 2005). Although the exact contribution of 
miRNAs, miRISC, AREs and ARE-BPs to mRNA decay has not been elucidated yet, 
recent studies have described a functional overlapping on mRNA stability between ARE- 
and miRNA-mediated regulatory pathways (Figure 9. It has been shown that miRNAs 
can functionally interact with ARE-BPs, and factors involved in miRNA metabolism, 
such as Dicer and Ago, are required for ARE-mediated decay (Jing et al., 2005). For 
example, it has been shown that HuR can bind AREs present in c-Myc 3’UTR at a site 
proximal to that recognized by let-7 miRNA. HuR appeared to facilitate the targeting of 
let-7-loaded miRISC to an adjacent region of HuR binding site, and to mediate the 
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reduction of c-Myc mRNA levels (Kim et al., 2009). Another example is the cooperation 
of ARE-BP TTP and miR-16 in targeting tumor necrosis factor-α mRNA for ARE-
mediated mRNA degradation (Jing et al., 2005). TTP does not bind directly miR-16 but it 
forms a complex with miRISC, and that complex recruits the deadenylase and the 
exosome for mRNA degradation. HuR can also relieve CAT-1 mRNA from miR-122 
repression upon stress in human liver cells (Bhattacharyya et al., 2006). 
 
 
 
 
 
 
 
 
 
Figure 9. Model of overlapping in the ARE - and miRNA-regulated 
deadenylation. Cooperation of ARE s-BPs, miRNAs, deadenylases and exosome 
is essential for the regulation of mRNA stability. The recruitment of the ARE -
BPs HuR or TT P to the ARE sequence assists the targeting of let-7- or miR-16-
loaded miRISC complexes, respectively, to the most proximal site to the ARE 
sequence. Taken from Zhang et al., (2010)   
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CHAPTER II 
EFFECT OF PARN EXPRESSION ON ENDOGENOUS GENE 
EXPRESSION UNDER DIFFERENT CELLULAR CONDITIONS 
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INTRODUCTION 
The steady-state levels of cellular mRNAs are determined by the balance between 
their biosynthesis and turnover. The turnover rates of individual mRNAs can vary in 
response to changes in the cellular environment and the mRNA poly(A) tail is one of the 
key structures required for correct regulation of mRNA degradation. The poly(A) tails are 
also critical for regulation of mRNA processing, translation and subcellular localization, 
such as nuclear export (Colgan and Manley, 1997; Mandel et al., 2008; Zhao et al., 
1999). Thus, the poly(A) tail is a fundamental cis-acting element that is essential for 
proper control of gene expression at several different levels in eukaryotes. The poly(A) 
tail is synthesized in the nucleus through a two-step polyadenylation reaction; an initial 
cleavage step, which specifies the 3’ end of the mRNA, followed by the synthesis of a 
200 adenosine residues tail to the 3’ end of the upstream cleavage product (reviewed in 
(Shatkin and Manley, 2000; Zhao et al., 1999). The polyadenylation reaction is by itself a 
highly regulated event and is used for example to regulate tissue or developmental 
specific gene expression and for cell growth control (Chuvpilo et al., 1999; Takagaki and 
Manley, 1998; Takagaki et al., 1996). Several examples of cases are known which links 
deficiencies in the polyadenylation machinery to disease development, including tumor 
formation (reviewed by (Scorilas, 2002).  
The polyadenylation reaction requires the assembly of a rather large number of 
interacting protein factors that recognize a relatively simple set of cis-acting signal 
sequence elements in the mRNA precursor. Cleavage stimulation factor (CstF) is one of 
the essential polyadenylation factors. CstF is active most likely as a dimer with each 
subunit consisting of three protein factors called CstF1, CstF2, and CstF3. CstF3 interacts 
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directly with the down-stream located GU-rich cis-acting element. Both the CstF1 and 
CstF2 subunits interact specifically with the carboxy-terminal domain (CTD) of RNA 
polymerase II largest subunit (RNAP II LS), likely facilitating the RNAP II-mediated 
activation of 3’ end processing (Hirose and Manley, 1998; McCracken et al., 1997). 
Moreover, 3’ end processing can be repressed following DNA damage as a result of the 
interaction between CstF1 and BRCA1-associated RING domain protein (BARD1, 
(Kleiman and Manley, 1999) and of the proteasome-mediated degradation of RNAP II 
(Kleiman et al., 2005). Studies from Dr. Kleiman’s lab have recently shown that cells 
with reduced levels of CstF display decreased viability following UV treatment, reduced 
ability to ubiquitinate RNAP II, and defects in repair of DNA damage (Mirkin et al., 
2008), supporting the idea that CstF plays a direct role in the DNA damage response. 
Although most of the polyadenylation factors have been described and the 
reaction is now relatively well understood, the mechanisms behind poly(A) removal are 
much less defined. In mammalian cells, the earliest and rate limiting step in mRNA decay 
is the removal of the mRNA poly(A) tail (Chen and Shyu, 2003; Wilusz et al., 2001). 
PARN is one of the three major poly(A) specific 3’ exoribonuclease identified in 
mammalian cells and characterized thus far (Mitchell and Tollervey, 2000; Parker and 
Song, 2004; Wu et al., 2005). It is expressed ubiquitously in all tissues of most eukaryotic 
organisms (Copeland and Wormington, 2001) and localizes both to the nucleus and the 
cytoplasm. PARN shows high specificity for single stranded poly(A) (Korner and Wahle, 
1997; Martinez et al., 2001), and its deadenylating activity is stimulated by the mRNA 5’ 
end located cap structure (Dehlin et al., 2000; Gao et al., 2001; Martinez et al., 2001; 
Nilsson et al., 2007; Wu et al., 2009). Although the exact function of PARN in the 
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nucleus is unknown, it has been established that the CBP80 (Balatsos et al., 2006) and the 
poly(A) binding protein 1 (PABPN1, (Gao et al., 2001) both inhibit PARN activity. 
Interestingly, the cap binding complex (CBC) has also been shown to play a role in 
polyadenylation by stabilizing the RNA/CstF complex formed in the nucleus and the 
depletion of CBC reduces the mRNA cleavage reaction (Flaherty et al., 1997). 
Dr. Cevher and colleagues (2010) found that the polyadenylation factor CstF1 
interacts strongly with the same region of PARN, the C-terminal domain, as its inhibitor 
CBP80. Like the previously described CstF/BARD1/BRCA1 complex, the CstF/PARN 
complex formation is stimulated upon UV light–treatment and participates in the 
inhibition of the 3’ cleavage reaction of polyadenylation upon DNA-damaging 
conditions. More importantly, they also showed that the CstF1/PARN interaction 
activates deadenylation in vitro and that UV treatment can activate nuclear PARN 
deadenylase activity. They provided evidence that the tumor suppressor BARD1 strongly 
activates deadenylation by PARN in the presence of CstF1 and that the siRNA-mediated 
knockdown of BARD1 decreases the UV-induced activation of deadenylation. In 
addition, their data showed that CBP80 and CstF1 could compete for binding to PARN, 
providing a mechanism to regulate PARN deadenylase activity in different cellular 
conditions. As part of those studies, I determined that these functional interactions 
correlate with changes in both stability and polyadenylation of different mRNA 
precursors, such as housekeeping genes and some clinically significant genes, upon UV 
treatment and that reduced expression of PARN is sufficient to revert the observed 
changes. Taken together, these results indicate that the CstF/PARN complex plays a role 
in the inhibition of 3’ cleavage of polyadenylation and the activation of deadenylation in 
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the nucleus upon DNA-damaging conditions, suggesting the existence of alternative 
mechanisms to regulate gene expression in different cellular conditions. This manuscript 
was the first report describing a mechanism of gene expression regulation in response to 
DNA damage that involves the deadenylation/polyadenylation machinery. 
RESULTS 
The data presented by Cevher and colleagues (2010) provided evidence that DNA 
damage induces the activation of PARN-mediated mRNA deadenylation in the nucleus. 
To further investigate this, I determined the expression levels of different endogenous 
mRNAs in cells treated by UV irradiation and with siRNAs targeting PARN. Briefly, 24 
h after transfection with the indicated siRNAs, cells were exposed to UV light and total 
nuclear RNA was purified at different time points after UV treatment. Gene expression 
was analyzed by real-time quantitative reverse transcription PCR (qRT–PCR). Random 
and oligo-(dT) primers were used for the RT reaction and qPCR reactions were 
performed using commercially available primers. First, the expression levels of two 
-actin, were analyzed under different cellular 
conditions. The qRT–PCR (Figure 10) analysis showed that the mRNA levels of these 
genes decreased under DNA-damaging conditions in cells treated with control siRNA. 
These data are consistent with earlier studies from Dr. Kleiman’s lab (Mirkin et al., 2008) 
and others previous observations (Dheda et al., 2004; Maccoux et al., 2007), which 
showed that GAPDH RNA expression can change significantly in different biological 
systems and under different conditions, and that these variations can lead to experimental 
error between analyzed samples when GAPDH is used as control. Interestingly, the UV-
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induced decrease in the mRNA levels of endogenous housekeeping genes was lost when 
the cells were treated with siRNAs targeting PARN (Figure 10).  
To determine the role of the BARD1/CstF/PARN complex formation in the 
regulation of mRNA levels, I used RNA samples from a stable cell line that expresses a 
BARD1 mutant in the threonine 734 (Kim et al., 2006). This mutant has a defect in DNA 
damage-induced BARD1 phosphorylation at the T734, which is important not only for 
the BARD1/CstF1 complex formation but also for the UV-induced inhibition of both 
mRNA 3’ end processing (Kim et al., 2006).  A similar pattern of changes in the mRNA 
levels of housekeeping genes was observed using the cell line expressing the BARD1 
mutant T734A (Figure 10), which did not show BARD1/CstF/PARN complex formation 
and activation of deadenylation after UV treatment (Cevher et al., 2010). These results 
indicate that BARD1/CstF/PARN complex formation has an important role to decrease 
the mRNA levels of housekeeping genes under DNA-damaging conditions, and thereby 
might contribute to the UV-induced decrease in the cellular levels of total mRNA. As it 
has also been shown that PARN can promote the deadenylation of AU-rich element 
(ARE)-containing mRNAs (Lai et al., 2003; Moraes et al., 2006), I also analyzed two 
ARE-containing mRNAs, that is, c-fos and c-myc, by qRT–PCR. Both mRNAs increased 
transiently under DNA-damaging conditions in cells treated with control siRNA and in a 
sarcoma cell line expressing WT BARD1 (Figure 10), in keeping with earlier studies that 
indicate that ARE elements within the 3’UTR can control mRNA levels under different 
cellular conditions. For example, ARE elements can decrease mRNA stability under non-
stress conditions and can increase mRNA stability after UV treatment in mammalian cells 
(Blattner et al., 2000; Bollig et al., 2002; Gowrishankar et al., 2005; Wang et al., 2000).  
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Figure 10. Analysis of the effect of PARN expression on endogenous gene 
expression after UV treatment. Real-time RT-PCR analysis of GAPDH, b-actin, c-fos 
and c-myc expression after UV-treatment using RNA samples from cells treated with 
control/PARN siRNA and from cells expressing WT/T734A BARD1 mutant. As the RT 
products of GAPDH from cells treated with control siRNA and not treated with UV 
were used as endogenous control, the log value corresponding to this sample was zero. 
The values shown in the figure have been adjusted to avoid the presentation of negative 
values. The data shown are the mean±s.e.m. from three independent experiments. Equal 
amounts of cDNAs were used in qRT–PCR reactions using primers specific for 
-actin, c-fos and c-myc mRNAs. Relative quantification was performed 
using standard curves of known amounts of total cDNA. The results shown are the 
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average of four PCRs from two different RNA extractions. Taken from Cevher et al., 
(2010)  
33 
 
Supporting my results, Blattner et al. (Blattner et al., 2000) showed that c-fos 
mRNA expression increased 45 min to 1 h after UV treatment and then dramatically 
decreased 2 h after UV treatment. Interestingly, PARN knockdown cells and cells 
expressing the T734A BARD1 mutant showed increase in the mRNA levels of both c-fos 
and c-myc in samples from cells not treated with UV (Figure 10). These results suggest 
that the BARD1/CstF/PARN complex has a role in decreasing the levels of short-lived 
mRNAs involved in the control of cell growth and differentiation, keeping their 
expression levels low under non-stress conditions. Both reduced expression of PARN and 
lack of BARD1/CstF/PARN complex formation have a slight effect on the UV-induced 
increase in the expression levels of these genes, suggesting that other mechanism(s) 
might be involved in determining the mRNA levels of these genes under DNA-damage 
conditions. Taken together, these results provide evidence that the BARD1/CstF/PARN 
complex has important roles in the regulation of the levels of different endogenous 
mRNAs under different cellular conditions. As proposed by Cevher and colleagues 
(Cevher et al., 2010), it is possible that the competition between CBP80 and CstF1 for 
binding to PARN under different cellular conditions could have a role in regulating the 
PARN activity and, therefore, the mRNA levels of different genes. 
DISCUSSION 
During the DNA repair process, control of gene expression either by transcription 
or by RNA processing is important to allow the access of the repair enzymes and to 
prevent the formation of deleterious proteins. Following UV irradiation, the cellular 
levels of mRNA are transiently decreased (Hanawalt, 1994; Ljungman, 1999). The 
cellular mechanisms involved in this response are unknown but imply a functional 
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interaction of the DNA repair, transcription, and RNA processing machineries. 
Supporting this idea, it has been described that polyadenylation is transiently inhibited 
upon UV treatment (Kleiman and Manley, 2001; Kleiman et al., 2005; Mirkin et al., 
2008).  As mRNA poly(A) tails are important for regulation of mRNA stability (Mandel 
et al., 2008; Shatkin and Manley, 2000; Zhao et al., 1999); changes in the 
polyadenylation levels either by activation/inhibition of the reaction or by controlling 
the balance between polyadenylation and deadenylation could account for some of the 
changes in mRNA levels after UV treatment. 
Previous work form Dr. Kleiman’s lab indicated that the polyadenylation factor 
CstF1 plays a coordinating role in the nuclear response to UV-induced DNA damage 
through its interaction with different factors in different cellular environments (Kleiman 
and Manley, 1999, 2001; Kleiman et al., 2005; Mirkin et al., 2008). Cevher and 
colleagues (Cevher et al., 2010) discovered that CstF1 interacts with the deadenylation 
factor PARN and that this interaction plays a role in inhibition of 3’ cleavage of the 
polyadenylation reaction and activation of deadenylation upon DNA damage treatment. 
They also found that BARD1 is not only involved in the UV-induced inhibition of 3’ 
cleavage (Kleiman and Manley, 1999, 2001) but also in the UV-induced activation of 
deadenylation in the presence of CstF1. Furthermore, Cevher and colleagues (Cevher et 
al., 2010) found that the previously identified nuclear CBP80/PARN deadenylation 
inhibitory complex decreased significantly in abundance upon DNA-damaging 
conditions, whereas the complex containing CstF1/PARN increased and that CstF1 
competed with CBP80 on binding to the same region of PARN. In fact, addition of CstF1 
and BARD1 to in vitro deadenylation reactions reverted the CBP80 inhibition effect on 
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PARN activity. As part of those studies, I determined that PARN knockdown had an 
effect on the stability and polyadenylation of different genes in different cellular 
conditions (Figure 10). Taken together, these results suggest that an interplay between 
these factors might control gene expression under DNA-damaging conditions by 
regulating polyadenylation/deadenylation.  
Based on the results presented in the work of Cevher and colleagues (Cevher et 
al., 2010), the following regulatory scenario was proposed (Figure 11). In the absence of 
DNA damage treatment, CBP80 binds to the C-terminal domain of nuclear PARN and 
inhibits its hydrolytic activity to ensure that PARN does not degrade the mRNA (Balatsos 
et al. 2006). In this situation, CBC is also known to enhance polyadenylation of pre-
mRNAs by increasing the stability of the RNA/CstF complex (Flaherty et al., 1997). As a 
result of these functional interactions, polyadenylation takes place and normal levels of 
total mRNA are observed. After DNA damage the BRCA1/BARD1-containing complex 
is recruited to sites of DNA repair to inhibit mRNA processing by RNAP II 
ubiquitination followed by degradation of the large subunit of RNAP II, or by covalent 
modification of other element/s of the complex. This facilitates DNA repair and/or 
prevent polyadenylation of aborted nascent mRNAs. If the UV-induced inhibition of 
mRNA 3’ cleavage is bypassed, the CstF/PARN interaction may provide a fall-back 
mechanism to ensure that erroneously polyadenylated mRNAs are eliminated by the 
activation of deadenylation. In this situation it has been proposed that CBP80 dissociates 
from PARN, allowing PARN to interact with the CstF1/BARD1 complex. This 
reorganization will result in an activation of deadenylation and contribute to the  
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Figure 11. A model of poly(A) tail dynamics after DNA damage.  In the 
absence of DNA damage treatment, CBP80 binds to nuclear PARN, inhibiting its 
deadenylase activity. After exposure to UV treatment, the CBP80 protein 
dissociates from PARN, allowing binding of PARN to the CstF1/BARD1 
complex. As a result of these functional interactions, polyadenylation is inhibited 
and a 5’ cap-dependent deadenylation decay pathway is activated, generating a 
decrease in the levels of total mRNA. Taken from Cevher et al. (2010) 
 
inhibition of polyadenylation. The final outcome will therefore be that polyadenylation is 
inhibited and deadenylation activated, contributing to the observed decrease in the levels 
of total mRNA under DNA-damaging conditions. A similar mechanism for control of 
gene expression has been described by others. For instance, Kim and Richter (Kim and 
Richter, 2006) have shown that the length of the cytoplasmic poly(A) tail is regulated by 
polyadenylation/deadenylation under different cellular conditions by the direct interaction 
of PARN with the polyadenylation factor CPEB. Moreover, Mauxion et al. (Mauxion et 
al., 2008) have shown that the tumor suppressor BTG2 is a general activator of the 
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cytoplasmic deadenylases Pop2/Caf1 and Ccr4, and that overexpression of BTG2 
accelerates the deadenylation of several reporters and endogenous transcripts, such as 
-actin. 
It has been shown that PARN co-purifies with essential nonsense-mediated decay 
factors (NMD), and that siRNA mediated down-regulation of PARN abrogates NMD 
(Lejeune et al., 2003). Although those reports focused on cytoplasmic PARN, it is 
possible that the activation of deadenylation by the CstF/PARN/BARD1 complex 
formation in the nucleus might signal the degradation of those erroneously 
polyadenylated prematurely terminated mRNAs, providing a mechanism of nuclear 
mRNA decay. Consistent with this previous work from Dr. Kleiman’s lab showed that 
prematurely terminated polyadenylated mRNA transcripts can be detected in vivo 
following DNA damage, especially under conditions when the CstF/BARD1/BRCA1 
checkpoint is not activated (Mirkin et al., 2008).  
Control of polyadenylation/deadenylation in the nucleus could represent a 
mechanism to regulate gene expression, which could be important to allow a rapid 
response during development or after stress treatment. For example, UV-treatment 
induces a decrease in the cellular levels of total mRNA to avoid the expression of 
deleterious proteins that may be harmful to the cell (Ljungman, 1999). UV-treatment also 
induces stabilization of ARE-containing mRNAs; such as c-fos, kin17, c-jun, IB and c-
myc (Blattner et al., 2000), to induce the expression of some proteins involved in DNA 
repair and cell cycle. My results indicate that PARN can decrease the stability of 
housekeeping genes upon DNA-damaging conditions and of ARE-containing genes upon 
non-stress conditions (Figure 10). Consistent with my results, it has been shown that 
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ARE-dependent deadenylation plays an important role in the mRNA decay of several 
oncogenes involved in regulation of cell growth and differentiation (Blattner et al., 2000; 
Lai et al., 2003; Moraes et al., 2006). My results indicate that gene expression of different 
genes, such as housekeeping and ARE-containing genes, might be regulated in the 
nucleus by the functional interaction between CstF/BARD1, CBP80 and PARN under 
different cellular conditions.  
As the tumor suppressor BARD1 is involved in this response, it is possible that 
malignant cells display altered levels of polyadenylation of certain mRNAs. Supporting 
this idea, enhanced polyadenylation has been detected in certain tumor cells (Scorilas, 
2002), polyadenylation is inactivated in M phase (Colgan et al., 1996; Colgan et al., 
1998), expression levels of poly(A) polymerase can interfere with cell growth (Zhao and 
Manley, 1998). Moreover, antiproliferative transcription factors, such as BTG2 and TOB, 
have been shown to enhance deadenylation, and the subsequent mRNA decay (Ezzeddine 
et al., 2007; Mauxion et al., 2008). Furthermore, the expression levels of certain ARE-
containing genes, such as c-jun and c-fos, increase significantly in cancer cells (Andersen 
et al., 2002; Milde-Langosch, 2005; Zajchowski et al., 2001). Interestingly, microRNAs, 
which have been either directly involved in human cancers or described as oncogenes or 
tumor suppressors, can direct rapid deadenylation of mRNAs and subsequent decay (Wu 
et al., 2006; Zhang et al., 2007a). 
Taken together, it can be concluded that regulation of the levels of 3’ end 
polyadenylation is an important event in controlling cell growth and in the response to 
certain stresses, such as UV treatment, and that polyadenylation/deadenylation process 
might represent a new mode of global regulation of gene expression.  
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CHAPTER III 
IDENTIFICATION OF GENES THAT ARE REGULATED BY PARN 
 DEADENYLATION IN DIFFERENT CELLULAR CONDITIONS   
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INTRODUCTION 
Almost all eukaryotic mRNA precursors, with the exception of histones, undergo 
a cotranscriptional cleavage followed by polyadenylation at the 3′ end. This first round of 
polyadenylation is considered a default modification for most mRNAs and confers 
stability. In contrast, activation of deadenylation alters the length of poly(A) tails, 
affecting mRNA stability, transport, or translation initiation, and hence gene expression 
(Zhang et al., 2010). Thus, mechanisms controlling deadenylation are highly regulated 
and play key roles in cellular responses, such as mRNA surveillance, DNA damage 
response (DDR), and tumor progression, as well as cell development and differentiation 
(Cevher and Kleiman, 2010; Cevher et al., 2010; Ji et al., 2009; Mayr and Bartel, 2009; 
Singh et al., 2009). Poly(A)-specific ribonuclease (PARN) deadenylase is one of the 
major poly(A) specific 3’ exoribonucleases identified in mammalian cells (Copeland and 
Wormington, 2001) that plays a role in DDR (Cevher et al., 2010). PARN can interact 
with the cleavage stimulation factor 1 (CstF1), and the CstF1/PARN complex formation 
has a role in the regulation of gene expression by inhibition of mRNA 3′ cleavage and 
activation of deadenylation upon DNA damage (Cevher et al., 2010). PARN, an mRNA 
decay enzyme, has been studied extensively in vitro at the biochemical levels but very 
little is known of its biological targets and its role in different cellular conditions. 
Recently, it has been shown that PARN regulates the expression of genes involved in 
mRNA metabolism, transcription, and cell motility in mouse myoblasts (Lee et al., 2012). 
My previous studies indicate that the CstF/PARN complex can decrease the mRNA 
levels of housekeeping genes under DNA-damaging conditions and of genes involved in 
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cell growth and differentiation under non-stress conditions (Figure 10; (Cevher et al., 
2010). 
Deadenylation of mRNA is regulated by microRNAs (miRNAs), adenylate-
uridylate–rich element (ARE) binding proteins, polyadenylation factors, and RNA 
binding (RB) factors that recognize cis-acting sequences in the target. About 12% of 
mammalian mRNAs bear important regulatory signal AREs in their 3′ untranslated 
regions (UTRs), which have been shown to play significant roles in mRNA stability 
regulation (Guhaniyogi and Brewer, 2001). PARN has been shown to be involved in 
ARE-mediated deadenylation and to promote tristetraprolin (TTP)-directed deadenylation 
in vitro (Lin et al., 2007). KH-type splicing regulatory protein recruits PARN to ARE-
containing mRNAs to initiate the poly(A) tail shortening that is followed by exosome-
mediated degradation (Gherzi et al., 2004). Interestingly, tumor suppressors, such as 
breast cancer type 1 susceptibility protein (BRCA1) and BRCA1-associated RING 
domain protein (BARD1), associated to the polyadenylation factor CstF1 have been 
shown to regulate deadenylation by functional interactions with PARN deadenylase 
(Cevher et al., 2010).  
Recently, work form Dr. Kleiman’s lab showed that the polyadenylation factor 
CstF1 can also form a complex with another tumor suppressor and DNA repair factor 
with compromised expression on most cancers, p53, resulting in the inhibition of mRNA 
3′ cleavage (Nazeer et al., 2011). Downstream signaling in the p53 pathway includes 
several cellular responses. The expression of a large number of genes involved in DNA 
repair, cell cycle arrest, and/or apoptosis is regulated by transactivating properties of p53. 
This occurs via specific DNA binding of the p53 protein to a p53 response element that is 
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found either in promoters or introns of target genes (Tokino and Nakamura, 2000). 
Transactivation-independent functions of p53 have also been described (Takwi and Li, 
2009). For example, certain miRNAs are regulated by p53, and these miRNAs cause 
dramatic changes in gene expression, offering an indirect p53-mediated control of gene 
expression at the posttranscriptional level (Chang et al., 2007).  
Extending those studies, work form Dr. Kleiman’s lab showed that p53 regulates 
not only mRNA 3′ cleavage (Nazeer et al., 2011) but also PARN-dependent 
deadenylation in different cellular conditions (Devany et al., 2013). As part of these 
studies, I also identified the mRNA targets of PARN in non-stress conditions. Together 
these results provide evidence of a unique feedback loop between p53 and PARN, in 
which PARN deadenylase keeps p53 levels low in non-stress conditions by destabilizing 
p53 mRNA through its 3′UTR, and the UV-induced increase in p53 activates PARN, 
representing a mechanism of gene expression regulation in a transactivation independent 
manner. 
RESULTS 
As PARN is involved in ARE-mediated deadenylation (Lin et al., 2007), 
promotes TTP-directed deadenylation (Lai et al., 2003), and decreases mRNA levels of 
ARE-containing genes under non-stress conditions (Figure 10; (Cevher et al., 2010), I 
decided to extend these studies and determine which mRNAs might be regulated by 
PARN using microarray assays. These assays were performed using RNA samples from 
HeLa cells treated with control or PARN siRNAs under non-stress conditions. The RNA 
samples were analyzed for gene expression using Affymetrix GeneChip Human Gene 1.0 
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ST array, which contains up to 290,000 different transcripts, by the Yale Center for 
Genome Analysis.  In collaboration with Dr. Bin Tian, UMDNJ-New Jersey Medical 
School, we performed pathway analysis of regulated genes using the Ingenuity Systems 
applications.  Pathway analysis results indicated that the p53 signaling pathway is the 
most significantly affected by PARN knockdown in non-stress conditions (Figure 12). In  
 
Figure 12. PARN deadenylase significantly affects the cellular expression of 
genes of the p53 pathway under non-stress conditions. Pathway analysis of 
significantly regulated genes by PARN. Nuclear RNA samples isolated from 
HeLa cells, treated with siRNAs targeting PARN or control, were analyzed using 
the Human Gene 1.0 ST GeneChip (Affymetrix) array. Significant genes were 
selected by t test (P value < 0.05). Analysis of canonical pathways was conducted 
by using data from Ingenuity Systems (www.ingenuity.com). The bar graph 
shows significance of pathway for regulated genes. P values were calculated using 
the Fisher’s exact test, and the −log (P value) values are displayed. Only the top 
five pathways are shown. Data represent three independent experiments. Taken 
from Devany et al., (2013)  
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addition, the p53-related gene network was found to be the most significantly regulated 
by network analysis and transcription factor analysis (Devany et al.; 2013). 
Approximately 75% of genes from the p53 signaling pathway, including p53, were 
affected by PARN knockdown, indicating that PARN expression has a specific effect on 
the expression of genes associated with p53-mediated signaling in non-stress conditions. 
Interestingly, under those conditions 20% of PARN mRNA targets in the p53 signaling 
pathway showed both miRNA target site(s) and an ARE(s) in their 3’UTRs (Table 1), 
suggesting that PARN might play a role not only in the ARE-mediated but also in 
miRNA-mediated deadenylation. 
I further confirmed the effect of PARN knockdown on the abundance of several 
transcripts in the p53 signaling pathway by quantitative (q)RT-PCR (Figure 13). 
Although there was a good correlation between the change observed in the microarray 
(Table 1) and that determined by qRT-PCR (Figure 13), the qRT-PCR showed changes of 
a greater magnitude than the array. These results support my previous study that showed 
that PARN can promote deadenylation and mRNA instability of FBJ osteosarcoma 
oncogene and myelocytomatosis oncogene (c-myc; Figure 10; (Cevher et al., 2010), 
keeping their expression levels low under non-stress conditions. Because PARN is a 
deadenylase, I expected an increase in the steady-state levels of its targets by PARN 
knockdown. However, my results show both up- and down-regulation of transcripts, 
suggesting complex effects of PARN knockdown on the expression of these mRNAs.   
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Gene 
Symbol
Description Fold Change
siRNA
PARN/CTRL
miRNA targeting sites at the 3’UTR ARE binding 
proteins
TP53 tumor protein p53 1.25 miR125b, miR504, miR25, miR-30d  Wig-1, HuR 
CHEK2 
CHK2 checkpoint homolog (S. 
pombe) 1.28
miR-24-2  
unknown 
CDK2 cyclin-dependent kinase 2 1.62 miR-372, miR-205, miR-885-5p, miR-103, miR-16    unknown 
ANXA1 annexin A1 1.22 miR-21, miR-584, miR-196a and miR-196b  unknown 
PEG10 paternally expressed 10 1.28 miR-122 unknown 
ID1 inhibitor of  DNA binding 1 1.25 miR-206 unknown 
FOS 
FBJ murine osteosarcoma viral 
oncogene 1.20
miR-29b, miR-155, miR-101, miR-221/222, miR-7b,  HuR, AUF1, 
TTP 
V-MYC 
v-myc myelocytomatosis viral 
oncogene 1.10
miR-26a, miR-24, miR-378, let-7, miR-17-92, miR-145, etc. HuR, AUF1, 
TTP 
PTEN phosphatase and tensin homolog 1.20
miR-21, miR-17, miR-20a,  miR-106b, miR-221, etc. 
TTP
RBL2 retinoblastoma-like 2 (p130) 1.22 miR302/367, miR-17, miR-20a, miR-106b, miR-290, etc. unknown 
MYO6 myosin VI 1.33 miR-143 and miR-145 unknown 
CD47 CD47 molecule 1.27 miR-34a, miR-155 and miR-326 unknown 
RB1CC1 RB1-inducible coiled-coil 1 -1.84 miR-138 unknown 
MBNL2 muscleblind-like 2 (Drosophila) -1.49 miR-302d, miR-372, miR-200c unknown 
BCL2L1 BCL2-like 1 -1.62 miR-21 unknown 
MMP1 matrix metallopeptidase 1 -1.23 miR-222 unknown 
THBS1 thrombospondin 1 -1.47 miR-17-92 HuR 
LIF leukemia inhibitory factor -1.30 miR-346, miR-494, miR-199 Unknown 
SMAD3 SMAD family member 3 -1.36 miR-135a, miR-140-5p, miR-582-3p, miR-582-5p, etc. Unknown 
IL8 interleukin 8 -1.93 miR-146a unknown 
PLAU plasminogen activator, urokinase -1.31 miR-193a  unknown 
FN1 f ibronectin 1 -1.59 miR-200c, miR-29b unknown 
CCND3 cyclin D3 -1.48 miR-16 unknown 
SERPINE1 
serpin peptidase inhibitor, clade E 
(type 1) -2.69
miR-146a, miRNA-449a/b, miR-30c and miR-301a 
HuR
HDAC1 histone deacetylase 1 -2.04 miR-449a unknown 
CTGF connective tissue growth factor -1.33 miR-17-92, miR-18, miR-19, miR-133 and miR-30   HuR 
CCND1 cyclin D1 -1.35
miR-15a, miR-16, miR-302, miR-205, let-7, miR-34a, etc. TTP, HuR, 
KSRP 
VEGFA vascular endothelial growth factor A -1.75 miR-297, miR-299, miR-567, miR-609, miR-222, etc. HuR
 
Table 1. Analysis for the presence of AREs and miRNA targeting sites in the 3’UTRs 
of genes from the p53 pathway affected by PARN expression in non-stress conditions. 
The expression of 141 genes from the p53 pathway was affected upon siRNA-mediated 
knockdown of PARN (Devany et al., 2013). 20% of these genes, including p53, showed 
both target sites. ARED 3.0 database and miRWalk were used for the search of ARE-
containing mRNAs and miRNAs validated targets (Dweep et al., 2011), respectively.  
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Figure 13. The effect of PARN knockdown on the abundance of several 
transcripts in the p53 signaling pathway by quantitative (q) RT-PCR. qRT-
PCR analyzing c-fos, c-myc, BCL-XL, HDAC1 and RB1CC1 mRNA levels using 
total RNAs samples isolated from cells treated with control/PARN siRNA. qRT-
PCR determinations give results similar to microarrays with regard to change in 
mRNA abundance after PARN knockdown. Taken from Devany et al., (2013) 
 
The microarray analysis showed a 1.25 fold increase in p53 mRNA level of 
PARN- to control- siRNA treated HeLa cells (Table 1). Importantly, consistent with the 
pathway analysis results, PARN knockdown resulted in a significant increase not only of 
p53 mRNA steady-state levels (Figure 14) but also of p53 protein levels (compare lanes 1 
and 2 in Figure 14), reaching expression levels similar to that observed after UV 
treatment. After UV treatment, the changes in the levels of p53 mRNA and p53 protein 
were PARN-independent, indicating there is (are) other mechanism(s) involved in the 
regulation of p53 expression during DDR. 
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Figure 14. PARN deadenylase significantly affects the cellular expression of 
genes of the p53 pathway under non-stress conditions. (A) p53 mRNA and (B) 
protein levels are affected by PARN expression. qRT-PCR and Western blot 
analysis of p53 expression after UV treatment using RNA or protein samples, 
respectively, from cells treated with control/PARN siRNA. A representative 
Western blot from three independent assays is shown. Topo II was used as 
loading control. The basal level of the proteins was arbitrarily set at 1.0 in the first 
lane, and relative fold change of each protein level is shown below each lane. 
Taken from Devany et al., (2013)  
A B
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To determine the effect of PARN expression on the stability of p53 mRNA, I 
compared mRNA decay rates of p53 transcript in cells treated with control- or PARN-
siRNA. The half-life of the p53 transcript was analyzed by qRT-PCR of nuclear RNA 
samples taken at different time points from PARN/control siRNA- and actinomycin D 
(Act-D)-treated cells (Figure 15). Previous observations have shown a similar half-life for 
the p53 transcript (Mazan-Mamczarz et al., 2003). My results indicate that PARN 
knockdown stabilized the p53 transcript (Figure 15). Because PARN is a deadenylase, the 
stabilization of p53 mRNA by its knockdown might be due to changes in the poly(A) tail 
length. Importantly, as shown in Figure 16, siRNA-mediated knockdown of PARN 
elongated the poly(A) tail length of p53 mRNA (quantification is shown in Figure 16B). 
Together, these results indicate that the PARN deadenylase affects p53 expression by 
regulating poly(A) length and hence mRNA stability in non-stress conditions. 
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Figure 15. PARN regulates p53 mRNA half-life. mRNA decay rates for p53 
and ACTIN, a non-PARN target gene, were determined by qRT-PCR at different 
time points following PARN/control siRNA- and Act-D treatment. The relative 
half-life of the p53 transcript was calculated from three independent samples. 
Errors represent the SD derived from three independent experiments. Western 
blot analysis of PARN expression after PARN/control siRNA and Act-D 
treatment is also shown. Taken from Devany et al., (2013) 
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Figure 16. PARN regulates p53 mRNA poly(A) tail length. (A) Nuclear RNA 
from PARN/control siRNA-treated cells was reverse-transcribed using an 
oligo(dT)-anchor primer and amplified using an oligonucleotide that hybridizes 
within the 3′ UTR of p53 mRNA. The products were separated on a nondenaturing 
PAGE and detected by ethidium bromide staining. An RT-PCR product from a 
non-PARN target gene (ACTIN exon 3–4) was used as a loading control. A 
representative PAGE from three independent assays is shown. Molecular weight 
standard (MWS, 100-bp ladder from Promega) is also included. (B) Quantification 
of poly(A) tail length was done by obtaining the density profile of control and 
PARN KD lanes using ImageJ software.  Taken from Devany et al., (2013) 
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DISCUSSION 
The studies presented in this dissertation contributed to a study that provided 
evidence of a unique feedback loop between p53 and PARN deadenylase, in which 
PARN keeps p53 levels low in non-stress conditions by destabilizing p53 mRNA, and the 
UV-induced increase in p53 activates PARN deadenylase regulating gene expression 
during DDR in a transactivation-independent manner. Several lines of evidence support 
this model. First, the C-terminal domain of p53 can activate PARN-dependent 
deadenylation in vitro and p53 expression levels correlate with levels of mRNA 
deadenylation (Devany et al., 2013). Second, those studies show the direct interaction of 
the C-terminal domain of p53 with the C-terminal domain of PARN and the existence of 
protein complexes of these factors in cellular nuclear extracts (Devany et al., 2013). 
Third, PARN significantly affects the cellular expression of genes in the p53 pathway 
under non-stress conditions and the stability and poly(A) length of the p53 mRNA 
(Figures 12-13 and 15-16). Fourth, PARN knockdown and UV treatment induce a similar 
increase in p53 expression (Figure 14). Finally, PARN regulates p53 expression through 
the ARE sequence present in the 3′ UTR of p53 mRNA (Devany et al., 2013). Taken 
together, these results provide insights into p53 function and the mechanisms behind the 
regulation of mRNA 3′ end processing in different cellular conditions.  
Together these studies show an alternative mechanism to regulate the expression 
levels of p53 based on the control of the steady-state levels of p53 mRNA by PARN 
deadenylase under non-stress conditions (Figure 17A). Supporting this, my previous 
studies indicate that PARN has a role in decreasing the levels of short lived mRNAs 
involved in the control of cell growth, DDR, and differentiation, keeping their expression 
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levels low under non-stress conditions (Figure 10, (Cevher et al., 2010). Under stress 
conditions, the induction of p53 expression is associated with a decrease in the levels of 
total poly(A) mRNA (Ljungman et al., 1999). Because mRNA poly(A) tails are important 
for the regulation of mRNA stability, it is possible that these changes of poly(A) mRNA 
levels might represent another mechanism of p53-mediated control of gene expression. In 
fact, studies from Dr. Kleiman lab indicated that an increase in the expression of p53 
inhibits the mRNA 3′ cleavage step of polyadenylation (Nazeer et al., 2011) and induces 
PARN deadenylase activity (Devany et al., 2013), suggesting that the p53 associated to 
the PARN/CstF/BARD1 complex might regulate gene expression by controlling the 
steady-state levels of mRNAs (Figure 17B). Considering that the p53 pathway is tightly 
controlled in cells (reviewed in (Vousden, 2006), the p53-associated control of mRNA 3′ 
processing machinery could represent an indirect mechanism to repress target gene 
expression at the posttranscriptional level. The antiproliferative factor BTG2 represents 
another example of a general activator of mRNA deadenylation by its direct interaction 
with the Pop2–Caf1 and Ccr4 deadenylases (Mauxion et al., 2008). This model is 
consistent with the idea proposed by Singh et al. (Singh et al., 2009) that the interaction 
of the 3′ processing machinery and factors involved in the DDR/tumor suppression might 
result in cell-specific 3′ processing profiles. 
Control of deadenylation could represent a mechanism to regulate gene 
expression in different cellular conditions, such as development, stress treatment, or 
different metabolic conditions. Supporting this idea, recently it has been shown that 
PARN regulates the expression of genes involved in mRNA metabolism, transcription, 
and cell motility in mouse myoblasts, resulting in PARN-dependent regulation of cell 
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motility and wound healing in those cells (Lee et al., 2012). Indeed, the Gene Ontology 
analysis presented in this dissertation also revealed significant down-regulation of genes 
involved in similar pathways (Table 1, (Devany et al., 2013), such as structure 
morphogenesis, cell adhesion, cell migration, and so on. Consistently, the microarray data 
presented here showed a decrease in the abundance of mRNA for several genes involved 
in cell motility, such as adenosine A2b receptor, ankyrin repeatcontaining domain 54, and  
 
 
 
Figure 17. Model for the regulation of expression of genes in the p53 pathway 
by PARN deadenylaseassociated p53 in different cellular conditions. (A) 
PARN deadenylase decreases the stability of the p53 mRNA in non-stress 
conditions. The AREs in the 3′ UTR of the p53 mRNA have an important role in 
this regulatory process. (B) Under DNA damage conditions, p53 protein 
accumulates, allowing its association to and activation of PARN deadenylase 
resulting in the decrease levels of target mRNAs in the p53-dependent DDR 
pathway. Taken from Devany et al., (2013)  
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collagen alpha-2 chain in PARN knock-down cells. However, the p53 signaling pathway 
was not reported by Lee et al. (Lee et al., 2012), suggesting cell-specific functions of 
PARN. Like Lee et al. (Lee et al., 2012), I also observed a decrease in the steady-state 
levels of some transcripts by PARN knockdown. However, it is not clear whether this 
reflects the function of PARN per se or is the indirect consequence of PARN’s effect on 
genes involved in other mRNA metabolic pathways, such as transcription and RNA 
processing factors. 
The p53 pathway is tightly controlled in cells (reviewed by (Vousden, 2006). The 
microarray data presented in this dissertation showed that the expression of 141 genes 
from the p53 pathway was affected upon siRNA-mediated knockdown of PARN. 
Interestingly, 20% of these PARN target genes, including p53, showed both miRNA 
targeting sites and ARE regulatory sequences in their 3’UTR (Table 1). This data 
suggests that PARN might mediate the deadenylation of its target mRNAs through both 
cis-acting elements present at 3’UTR. This is consistent with the model proposed in Jing 
et al. 2005 (Jing et al., 2005) and by myself (Zhang et al., 2010) that both miRNAs and 
AREs functionally overlap and contribute to the control of mRNA stability. The 
characterization of the regulatory elements in the 3′ UTR of p53 and the factors involved 
in this PARN-dependent regulatory pathway may allow us to better understand the 
mechanisms that control p53 expression and to find alternative strategies for treating 
tumorigenesis and metastasis in various cancers. 
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CHAPTER IV 
MECHANISMS BEHIND PARN-MEDIATED REGULATION OF THE STEADY- 
STATE LEVELS OF GENES INVOLVED IN STRESS RESPONSE PATHWAYS 
UNDER NON-STRESS CONDITIONS  
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INTRODUCTION 
Modulation of the length of poly(A) tail of an mRNA by the polyadenylation/ 
deadenylation machinery is a widespread strategy used to control mRNA stability and 
gene expression in different cellular conditions. The dynamic nature of the mRNA 3’-end 
processing machinery allows the regulation of the steady-state levels of different mRNAs 
and has the potential to contribute to the cells rapid response to stress. Nuclear poly(A) 
specific ribonuclease (PARN), a poly(A) specific 3’ exoribonuclease, has been shown to 
play a role in DDR. The association of PARN with the cleavage stimulation factor 1 
(CstF1) inhibits mRNA 3’ cleavage and activates deadenylation upon UV-induced DNA 
damage (Cevher et al., 2010). Besides, PARN is also activated by tumor suppressors and 
DNA repair factors with compromised expression on most cancers, such as 
BARD1/BRCA1 (Cevher et al., 2010) and p53 (Devany et al., 2013). Interestingly, 
PARN regulates the stability of mRNAs of genes involved in DDR, such as c-myc, c-fos, 
c-jun, and transcripts in the p53 and BARD1/BRCA1 pathways, keeping their levels low 
under non-stress conditions (Cevher et al., 2010; Devany et al., 2013; Moraes et al., 
2006) 
Deadenylation, and consequently mRNA stability, is under the control of cis-
acting regulatory elements present in the 3’ untranslated region (3’UTRs) of eukaryotic 
mRNAs, such as alternative polyadenylation (APA) signals, AU-rich elements (AREs) 
and microRNA (miRNA) targeting sites. The use of different APA signals generates a 
diversity of mRNA isoforms that carry different arrangements of AREs and miRNA 
target sites and exhibit different stabilities (Figure 5). Both sequence and location of these 
elements are between these cis-acting elements and the 3’ processing machinery is 
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highlighted in cancer cells (Mayr and Bartel, 2009; Singh et al., 2009) and during cell 
differentiation (Ji et al., 2009; Sandberg et al., 2008; Zlotorynski and Agami, 2008), 
where changes in the length of the 3’UTR of different mRNAs affect cell expression 
patterns. These sequence elements recruit trans-acting factors that regulate those 
processes and affect gene expression, such as miRNA-induced silencing complex 
(miRISC), ARE-binding proteins (ARE-BPs), polyadenylation factors, and RNA binding 
(RB) factors. Many studies support the idea that miRNAs destabilize mRNA through 
deadenylation pathways, while AREs function in mRNA stability by either preventing 
mRNA from degradation by exosome or by recruiting the exosome to decrease the 
mRNA stability (Zhang et al., 2010).  
ARE sequences are frequently present in genes that encode tightly regulated 
proteins involved in cell growth regulation, cell differentiation and responses to external 
stimuli. The destabilizing functions of AREs are important because in their absence 
proto-oncogenes, such as c-fos, c-myc, c-jun, might become oncogenes (Schiavi et al., 
1992). Other mRNAs, such as IL-3, need AREs in order to inhibit the growth of autocrine 
tumor mast cells by an immunosuppressant cyclosporin A (Nair et al., 1994). A number 
of trans-acting factors, known as ARE-BPs, regulate ARE-mediated decay by either 
inhibiting or activating deadenylation, and subsequently change the stability of ARE-
containing mRNAs (Barreau et al., 2005). ARE-BPs regulate ARE-mediated decay of 
mRNAs by recruiting or blocking the recruitment of the deadenylases to the target 
mRNAs in different cellular conditions (Figure 6). PARN has been shown to be involved 
in ARE-mediated deadenylation and to promote tristetraprolin (TTP)-directed 
deadenylation in vitro (Lin et al., 2007). KH-type splicing regulatory protein (KSRP) 
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recruits PARN to ARE-containing mRNAs to initiate the poly(A) tail shortening that is 
followed by exosome-mediated degradation (Gherzi et al., 2004).  
miRNAs comprise a large family of small, non-coding single-stranded RNAs, 
which are predicted to mediate more than 60% of all protein-coding genes in mammalian 
cells (Friedman et al., 2009). From protozoans to plants to mammals, miRNAs play key 
roles in a broad range of biological processes, in the form of ribonucleoprotein 
complexes, known as miRISCs, which deliver miRNAs to their mRNA targets. It is 
believed that miRNA function in gene expression regulation mostly through post-
transcriptional events, either through translation regulation and/or through deadenylation 
activation, which leads to mRNA degradation, and consequently the modulation of gene 
expression (Figure 8). It is conventionally accepted that miRNAs function as a negative 
regulator of mRNA expression; however, under certain conditions, such as quiescence or 
in oocytes, miRNA-mediated upregulation of target mRNAs has also been demonstrated 
(Fehr et al., 2012; Truesdell et al., 2012). Interestingly, miRNA-expression profiles 
change during DDR (Pothof et al., 2009), suggesting a role of miRNA-mediated pathway 
in controlling gene expression during this response.  
Briefly, miRISCs are assembled in the cytoplasm where one strand of the mature 
miRNA duplex is incorporated along with Argonaute (Ago) proteins, which represent the 
catalytic activity, and then the miRISC is directed to its mRNA targets 3’UTR through 
interactions with sites of imperfect complementarity (Bartel, 2009; Bushati and Cohen, 
2007; Filipowicz et al., 2008; Friedman et al., 2009; Ghildiyal and Zamore, 2009; 
Hutvagner and Zamore, 2002; Liu et al., 2004; Martinez et al., 2002; Meister et al., 
2004). Besides 3’UTRs, miRNAs can also modulate cellular gene expression by targeting 
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the 5’UTRs, coding regions promoters, and gene termini (Huang et al., 2012; Kim et al., 
2008; Lytle et al., 2007; Place et al., 2008; Tay et al., 2008; Younger and Corey, 2011a, 
b). Additional protein components are critical for miRNA-mediated deadenylation. For 
example, Ago recruits the GW182 factor (TNRC6 in humans, (Lazzaretti et al., 2009; 
Takimoto et al., 2009; Zipprich et al., 2009), and cytoplasmic poly(A) binding protein 1 
(PABPC1), both of which contribute to miRNA-mediated poly(A) removal (Fabian et al., 
2009; Jinek et al., 2010; Zekri et al., 2009). One of the best studied deadenylases 
involved in miRISCs is the CAF1/CCR4/NOT1 complex (Zekri et al., 2009). Either the 
knockdown of CCR4 or NOT1 (Behm-Ansmant et al., 2006; Fabian et al., 2009) or the 
overexpression of CCR4 or CAF1 mutants significantly reduce miRNA-mediated 
deadenylation and mRNA decay (Piao et al., 2010). Pan2-Pan3 deadenylase has also been 
described to promote miRNA-mediated deadenylation and then trigger mRNA decay 
(Chen et al., 2009). However, the functional interaction of miRISC and PARN 
deadenylase has not been elucidated.  
The role of miRNA-mediated deadenylation in different biological processes has 
been studied in different systems. For example, it has been shown that let-7-associated 
miRISCs directly activate deadenylation of target mRNAs in a cell-free system 
(Wakiyama et al., 2007), and that the overexpression of let-7 miRNAs decreases the 
mRNA levels of oncogenes, such as c-myc and RAS (Johnson et al., 2005; Sampson et 
al., 2007). These results indicate that a decrease in let-7 miRNA levels might lead to 
tumorigenicity in lung and colon cancers (Akao et al., 2006; Johnson et al., 2005)). The 
processing of let-7 precursors is blocked by lin-28B, a putative RNA-binding protein 
highly expressed in hepatocellular carcinoma (Wang et al., 2010). The overexpression of 
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lin-28B enhances tumorigenecity by increasing the expression of the oncogenic let-7 
targets (Maeda et al., 2010). miR-125b has also been described to participate in miRNA-
mediated deadenylation and in the reduction of cellular abundance of targeting mRNAs  
(Wu and Belasco, 2005). Interestingly, the overexpression of miR-125b correlates with 
the downregulation of lin-28  (Eda et al., 2009). These studies indicate that miRNAs 
might play crucial roles in multiple oncogenic pathways. In fact, it has been suggested 
that miRNAs might function as oncogenes and promote cancer development by 
negatively regulating tumor suppressor genes and/or genes that control cell differentiation 
of apoptosis (Zhang et al., 2007a; Zhang et al., 2007b); .
  
While most studies traditionally have focused on cytoplasmic miRNA-mediated 
pathways, miRNA’s nuclear functions have begun to emerge in recent years (Cernilogar 
et al., 2011; Robb et al., 2005; Tan et al., 2009)). Subcellular localization studies in 
mammalian cells have shown that elements from the miRISC, such as Ago-1 and Ago-2, 
are localized in the nucleus (Ahlenstiel et al., 2012; Ohrt et al., 2008; Tan et al., 2009). 
Nuclear-cytoplasmic shuttling proteins, such as TNRC6A and CRM1, navigate loaded 
miRISC into the nucleus, leading miRNA-mediated gene silencing (Nishi et al., 2013). It 
has also been shown that elements from the miRISC play a role in transcriptional 
regulation (Cernilogar et al., 2011), in alternative splicing (Liu et al., 2012), and in 
epigenetic regulation and chromatin organization (Pushpavalli et al., 2012). These 
findings reinforce the functional RISC components activity in the nucleus, suggesting 
miRNA pathways can be adapted to function in the mammalian nucleus. Deep 
sequencing analysis has shown that a subset of miRNAs is predominantly localized in the 
nucleus (Liao et al., 2010). In fact, nuclear miRISCs are also able to specifically cleave 
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their target mRNAs with high efficiency, resulting in miRNA-mediated gene silencing in 
the nucleus (Nishi et al., 2013). Interestingly, nuclear miRISCs are loaded in the 
cytoplasm and imported into the nucleus, and their nuclear accumulation depends on the 
presence of RNA targets (Ohrt et al., 2008). However, despite the significant progress 
made in documenting nuclear miRISC, the mechanism(s) underlying miRNA-mediated 
regulation of gene expression in the nucleus (is) are not clear and the participating 
nuclear deadenylase and other factors remain(s) to be elucidated.  
Interestingly, some of the seed signals recognized by miRNA overlap with AREs 
in the 3′UTR (Figure 9). Although the exact contribution of miRNAs, miRISC, AREs and 
ARE-BPs to mRNA decay has not been elucidated yet, recent studies have described a 
functional overlap between ARE- and microRNA-mediated mRNA turnover pathways. It 
has been described that miRNAs can functionally interact with ARE-BPs, and that Dicer 
and Ago are required for ARE-mediated decay (Jing et al., 2005). Moreover, it has been 
shown that the ARE-BP HuR can bind AREs present in c-myc 3′UTR at a site proximal 
to that recognized by let-7 miRNA. HuR appeared to facilitate the targeting of let-7-
loaded miRISC to an adjacent region of HuR binding site, and to mediate the reduction of 
c-Myc mRNA levels (Kim et al., 2009). Another example is the cooperation of ARE-BP 
TTP and miR-16 in targeting tumor necrosis factor-α mRNA for ARE-mediated mRNA 
degradation (Jing et al., 2005). TTP does not bind directly to miR-16 but it forms a 
complex with miRISC, and that complex recruits the deadenylase and the exosome for 
mRNA degradation. HuR can also relieve CAT-1 mRNA from miR-122 repression upon 
stress in human liver cells (Bhattacharyya et al., 2006).  
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As mentioned above, my results indicate that PARN regulates the stability of the 
p53 transcript keeping its levels low under non-stress conditions (Cevher et al., 2010; 
Devany et al., 2013; Moraes et al., 2006). The tumor suppressor p53 is a nuclear 
phosphoprotein that acts as a transcription factor in response to several stress stimuli. 
Downstream signaling in the p53 pathway includes numerous cellular responses. The 
expression of a large number of genes involved in DNA repair, control of cell cycle and 
apoptosis, differentiation, senescence and cellular homeostasis are regulated by 
transactivating properties of p53 (Lane and Levine, 2010; Reinhardt and Schumacher, 
2012; Vousden and Prives, 2009; Wiesmuller, 2001). This occurs via specific DNA 
binding of the p53 protein to a p53 response element that is found either in promoters or 
introns of target genes  (Tokino and Nakamura, 2000). The p53 pathway can be also 
regulated by signaling downstream from p53 (e.g., MDM2, MDM4, INK4/ARF), p53 
isoforms (e.g., p63, p73), and microRNAs (e.g., miR-34). Transactivation-independent 
functions of p53 have also been described (Takwi and Li, 2009). For example, certain 
miRNAs are regulated by p53, and these miRNAs cause dramatic changes in gene 
expression, offering an indirect p53-mediated control of gene expression at the 
posttranscriptional level (Chang et al., 2007). Although many reports have been 
published about control of p53 protein expression and its effect on downstream pathways, 
very little is known of the mechanisms behind the control of p53 mRNA steady-state 
levels in different conditions (Vilborg et al., 2010) . 
In this study, I found that PARN deadenylase regulates the mRNA stability of one 
of its targets, the p53 mRNA (Devany et al., 2013), via a nuclear miRNA-mediated 
pathway. I found that Ago-2 activates PARN deadenylase activity by directly interacting 
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with the N-terminal domain of PARN and forming a complex in the nucleus.  
Interestingly, the binding of PARN to the p53 mRNA 3’UTR depends on cis-acting 
signals present in this region, such as AREs and miRNAs target sites, and Ago-2 
expression. I showed that the miR-125b-loaded miRISC recruits PARN to the target p53 
mRNA leading to a change in p53 mRNA steady-state level. These results reveal a novel 
regulatory pathway wherein PARN deadenylase plays a role in not only ARE- but also 
miRNA-mediated regulation of mRNA stability and, consequently, expression level. This 
regulatory pathway indicates a novel nuclear function of miRISC in mammalian cells as 
well as provides new insights in the p53 pathway. 
RESULTS 
PARN regulates p53 expression through its association with p53 3’UTR. 
Previously, I have shown that PARN plays a role regulating p53 mRNA steady-
state level through destabilizing p53 transcript (Figures 14-16 and Table 1, (Devany et 
al., 2013). In this part of study, I investigated the mechanisms underlying regulation of 
p53 mRNA stability by PARN deadenylase. First I tested if PARN could associate with 
p53 mRNA under non-stress conditions. RNA immunoprecipitation (RIP) assays using 
antibodies against PARN showed that p53 mRNA can form a complex with PARN in 
samples from cross-linked RKO cells (Figure 18), indicating that PARN can regulate p53 
mRNA stability by, most probably, an indirect association to the 3′ UTR. RIP assays also 
showed that PARN can form a complex with c-myc RNA (Figure 18), which is another 
target of PARN deadenylase (Cevher et al., 2010).  
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As most of the regulatory elements involved in PARN-mediated regulation of 
mRNA stability are located in the 3′ UTR of the genes, I decided to determine whether 
the PARN-induced decrease of p53 mRNA levels under non-stress conditions is through 
this region of p53. Firefly luciferase plasmids were constructed in a way that luciferase 
gene is under the control of either the wild type p53 3′ UTR or the vector 3′UTR (Figure 
19A). Recently, a G-quadruplex structure that protects the p53 mRNA from degradation 
 
 
Figure 18. PARN can interact with p53 and c-myc under non-stress 
conditions. (A) RIP of endogenous genes from RKO cells. The extracts were 
immunoprecipitated with either anti-PARN or IgG antibodies. The endogenous 
nuclear RNA immunoprecipitated with the antibodies was quantified by qRT-
PCR using primers specific for each gene. (B) The bar graph indicates the 
quantification of RNA immunoprecipitated with the indicated antibodies. The 
qRT-PCR values were calculated from three independent samples. Taken from 
Devany et al. (2013) 
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upon stress by binding to heterogeneous nuclear ribonucleoprotein H/F has been 
described (Decorsiere et al., 2011). This structure, which is located downstream of the 3′ 
cleavage site, was not included in this luciferase construct. To investigate the role of p53 
expression in these luciferase assays, I used a group of isogenic cell lines that express 
different levels of p53: the colon cancer HCT116 and p53-null HCT116 cell lines and the 
colon carcinoma RKO and RKO-E6 (low p53 levels) cell lines. A significant increase in 
firefly/Renilla ratio for the construct with the p53 3′UTR relative to the control construct 
was detected in RKO/RKO-E6 and HCT116/HCT116 p53−/− cells treated with PARN 
siRNA (Figure 19B). RKO/RKO-E6 and HCT116/HCT116 p53−/− cells showed similar 
ratios for the expression of firefly/Renilla luciferase indicating that the PARN-mediated 
regulation of p53 expression is p53-independent.  
Since PARN could associate with p53 transcript, and its role in the control of p53 
expression is through p53 mRNA 3’UTR region, next I tested if PARN binds to p53 
mRNA at its 3’UTR. Constructs carrying the p53 3’UTR (luc-p53) or not (luc-vector) 
were transfected into RKO cells. Then RIP assays using antibodies against PARN or IgG 
were performed followed by qRT-PCR with luciferase primers for quantification. The 
RIP assays indicate that PARN can form a complex with the luciferase mRNA carrying 
the 3′ UTR of p53 (Figure 19). Interestingly, the 3′ UTR of p53 mRNA also contains 
ARE that associates with ARE-binding proteins, such as wild-type p53-induced gene 1 
(Vilborg et al., 2009) and HuR (Zou et al., 2006) and regulates p53 mRNA steady-state 
levels. Importantly, it has been shown in Dr. Kleiman’s lab that the replacement of the 
ARE sequence from the p53 3′ UTR (noARE construct) significantly increased the 
firefly/Renilla ratio compared with the WT p53 3′ UTR construct (Devany et al., 2013),   
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Figure 19. PARN regulates p53 expression through ARE sequence present in 
the 3′ UTR of p53 mRNA. (A) Diagram of firefly luciferase reporter constructs 
with the vector or 3′ UTR sequence from the p53 gene. Polyadenylation signals 
(PAS) are indicated. (B) Constructs carrying the p53 3′ UTR (p53) or not (vector) 
were transfected in cells treated with PARN or control siRNAs. The ratios of the 
firefly/Renilla values for the p53 construct relative to the vector construct are 
shown. The firefly/Renilla values were calculated from three independent 
samples. Errors represent the SD derived from three independent experiments. 
Taken from Devany et al., (2013) 
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luciferase from the constructs carrying the AREs but not from the constructs without the 
AREs, indicating that the AREs in the p53 3′ UTR are necessary for PARN-mediated 
regulation of p53 expression. Supporting this idea, RIP assays presented in this 
dissertation indicate that PARN can form a complex with the luciferase mRNA carrying 
the 3′ UTR of p53 and this is abolished when AREs are replaced by other sequences 
(Figure 20). Together, these results indicate that the ARE in the p53 3′UTR is important 
for the PARN-mediated regulation of p53 mRNA steady-state levels and that this 
regulation is p53-independent. 
 
Figure 20. PARN can interact with p53 3’UTR under non-stress conditions. 
RIP of cells transfected with luciferase constructs carrying either the p53 3’UTR 
(luc-p53) or not (luc-vector). A construct with the ARE-replaced in the p53 3′ 
UTR (noARE) was also analyzed. The extracts were immunoprecipitated with 
either anti-PARN or IgG antibodies. Nuclear RNA immunoprecipitated with the 
antibodies was quantified by qRT-PCR using primers specific for luciferase gene 
and actin gene.   
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The miRISC component Ago-2 binds to PARN deadenylase in the nucleus. 
PARN regulates the stability of ARE-containing mRNAs keeping their levels low 
under non-stress conditions (Cevher et al., 2010; Devany et al., 2013; Moraes et al., 
2006)). Interestingly, 20% of PARN mRNA targets in the p53 signaling pathway showed 
not only AREs but also miRNA target sites in their 3’UTRs (Chapter III, Table 1). RNA-
binding proteins, such as ARE-binding proteins and elements of the miRISC, are 
necessary to recruit an active deadenylase to its mRNA substrates leading to mRNA 
deadenylation and degradation. Although the miRISC has been shown to functionally 
interact with several deadenylases, its functional interaction with PARN has not been 
elucidated. To test the possibility that elements of the miRISC might also be involved in 
PARN-dependent deadenylation, I analyzed the potential interaction of PARN and Ago-
2. First, the localization of Ago-2 and PARN in cellular fractions from HCT116 cells was 
analyzed (Figure 21). Both Ago-2 and PARN were present in the nuclear fraction.  
Topoisomerase II (Topo II) and actin were used as subcellular fractionation controls. As 
nuclear deadenylation is activated upon UV-induced DNA damage (Cevher et al., 2010), 
I have included stress conditions in this study. Interestingly, Ago-2 shuttled between the 
nuclear and cytoplasmic compartment in response to UV treatment, indicating a dynamic 
intracellular distribution of Ago-2 in response to DNA damage and suggesting a possible 
role of miRNA pathway in control of gene expression during DDR. The previously 
described UV-induced increase in nuclear PARN (Cevher et al., 2010) was also observed.  
To test whether PARN physically associates with Ago-2 I performed co-
immunoprecipitation (co-IP, Figure 22) and pull-down (Figure 23) assays. The co-IPs 
indicate that PARN can form (a) protein complex(es) with Ago-2 in nuclear extracts (NE)  
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Figure 21. Both PARN and the miRISC component Ago-2 are present in the 
nuclear fraction. Both PARN and Ago-2 are present in the nuclear fraction. Ago-
2 shuttles between the nuclear and cytoplasmic compartment in response to UV 
irradiation. Equivalent amounts of cytoplasmic and nuclear fractions of HCT116 
cells were subjected to SDS-PAGE and proteins were detected by immunoblotting 
using antibodies against Ago-2 and PARN. Both nuclear (nPARN) and 
cytoplasmic (cPARN) isoforms of PARN are shown. Topo II and actin are used as 
subcellular fractionation control. The basal level of the proteins was arbitrarily set 
at 1.0 in the first lane, and relative fold change of each protein level is shown 
below each lane. Quantifications were done with Image J software 
(http://rsb.info.nih.gov/ij/). 
 
from HCT116 cells. Interestingly, the complex was detected in both non-stress conditions 
and after UV treatment. As samples were treated with RNase A, the observed interactions 
were probably not due to an RNA tethering effect. The results showed that PARN can 
interact directly with Ago-2 and that the N-terminal domain, which contains the nuclease 
activity and is responsible for cap-binding properties of PARN (Martinez et al., 2001), is 
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-actin
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important for this interaction (Figure 23). Together these results indicate that PARN can 
interact with the miRISC component Ago-2 to form (a) complex(es) independently of 
miRNA and stress conditions. 
 
 
 
Figure 22. The miRISC component Ago-2 interacts with PARN deadenylase 
to form a protein complex in the nucleus. PARN and Ago-2 could form (a) 
complex(es) in NEs of HCT116 cells independently of UV treatment. The NEs 
were immunoprecipiated with anti-PARN (Left) and anti-Ago-2 (Right). 
Equivalent amounts of the pellets (IP) and supernatants (SN) were resolved by 
SDS-PAGE and proteins were detected by immunoblotting using antibodies 
against PARN and Ago-2. Antibody against Topo II was used as a control.   
  
Input    IP-PARN  SN                           Input  IP-Ago-2         SN
UV:     - +   - +   - +  - +          - + - +
- PARN-
- Topo II-
- Ago-2 -
1       1.8     2.0  2.3  0.3  1.1                  1 1.3     2.5 3.2      1.1  2.0
1 0.8 1.0  0.9     1.0     0.9    1 0.5   1.1     1.0       1.1 1.0
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Figure 23. The miRISC component Ago-2 interacts directly with PARN 
deadenylase in vitro. Ago-2 interacts directly with the N-terminal domain of 
PARN. Immobilized His-PARN on nickel beads was incubated with GST-Ago-2 
(left panel). Bound proteins were eluted, detected by Western blotting with 
antibodies against PARN or Ago-2. 5% of His-PARN and GST-Ago-2 used in the 
reaction are shown as input. Immobilized GST-Ago-2 or GST on glutathione 
beads were incubated with full-length (FL), N-terminal domain (NTD) or C-
terminal domain (CTD) of His-PARN (right panel). Bound proteins were detected 
by immunoblotting as before. 5% of His-PARN derivatives used in the reaction 
are shown as input.  
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Ago-2 has a role in the UV-induced activation of nuclear PARN deadenylase 
activity. 
To test whether Ago-2 has a direct influence on PARN deadenylase activity I 
performed in vitro reconstituted deadenylation assays, where I monitored the 
deadenylation of a radiolabeled L3(A30) RNA substrate in a reaction using limiting 
amounts of His-PARN and increasing amounts of GST-Ago-2. Addition of GST-Ago-2 
enhanced the deadenylation activity of PARN up to 2.3 folds (Figure 24), indicating that 
Ago-2 is an activator of PARN activity in a cell-free system and in the absence of 
miRNA. Importantly, deadenylation activity was not detected when using GST-Ago-2 
alone. Extending these results, I investigated the role of Ago-2 in nuclear deadenylation 
by performing siRNA mediated knockdown of Ago-2 in HCT116 cell line and then 
analyzing the UV-induced activation of deadenylation. As described in previous studies 
(Cevher and Kleiman, 2010; Devany et al., 2013), Figure 25 shows that deadenylation 
activity in NEs of HCT116 cells treated with control siRNA increased significantly after 
UV treatment. Interestingly, deadenylation, especially after UV-treatment, was 
completely abolished in samples from cells treated with siRNA targeting Ago-2. These 
results indicate that in the presence of Ago-2, which is involved in cytoplasmic 
deadenylation processes, PARN-mediated deadenylation is activated both in vitro and in 
samples from HCT116 cells. Together these results suggest that Ago-2/PARN complex 
formation activates PARN deadenylase and, therefore, might regulate gene expression. 
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Figure 24. Ago-2 enhances PARN-mediated deadenylation in vitro. Ago-2 can 
activate PARN-dependent deadenylation in vitro. Deadenylation assays were 
performed in the presence of radiolabeled capped L3(A30) RNA substrate as 
described (Cevher et al., 2010), using different concentrations of His-PARN and 
increasing amount of GST-Ago-2. Positions of the polyadenylated RNA L3(A30) 
and the L3 deadenylated product are indicated. Numbers beneath gel lane indicate 
relative deadenylation (RD), which was calculated as [L3 fragment/(L3(A30) + L3 
fragment)] x 100. Quantifications were done with Image J software.  
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Figure 25. siRNA mediated knockdown of Ago-2 abolishes UV-induced 
activation of deadenylation. siRNA-mediated knockdown of Ago-2 abolishes 
UV-induced activation of deadenylation in HCT116 cells. The protein levels of 
Ago-2 and Topo II were analyzed by Western blotting after Ago-2/control siRNA 
treatment (Left). A representative deadenylation reaction from three independent 
assays is shown (Right). NEs from HCT116 cells treated with Ago-2/control 
siRNA and UV irradiation, and allowed to recover for 2 h were analyzed for 
radiolabeled L3(A30) deadenylation as described (Cevher et al., 2010). RNAs 
were extracted and deadenylation reactions were analyzed as in Figure 24. 
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Association of PARN to its target mRNAs requires Ago-2. 
As Ago-2 is the core component of the miRISC complex, which delivers miRNAs 
and deadenylases to their mRNA targets, and my results indicate that it binds directly to 
PARN enhancing its deadenylase activity (Figures 22-25), I wonder whether Ago-2 plays 
a role in PARN-mediated expression regulation of p53, one of its targets, under non-
stress conditions. To test these NEs from HCT116 cells treated with control, PARN, Ago-
2 or both PARN/Ago-2 siRNAs were analyzed by Western blot for p53 expression. 
Interestingly, p53 protein levels increased in samples from cells treated with either Ago-2 
or PARN siRNA (Figure 26), suggesting that both factors might be involved in the same  
 
 
 
Figure 26. siRNA-mediated knockdown of Ago-2 and PARN have similar 
effects on p53 expression levels. NEs from HCT116 cells treated with control, 
PARN, Ago-2, or both PARN/Ago-2 siRNAs were analyzed by Western blot for 
p53 expression. Topo II was used as loading control (not shown). The p53 protein 
expression levels were calculated from three independent samples. The basal level 
of the proteins was arbitrarily set at 1.0 in the control siRNA-treated sample.   
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p53 regulatory pathway. In fact, the double knockdown of PARN and Ago-2 resulted in 
similar p53 protein levels to Ago-2 knockdown alone indicating that Ago-2 is necessary 
for PARN-mediated reduction of p53 protein levels.  
Next, I tested whether Ago-2 could facilitate the recruitment of PARN to its 
mRNA targets. My previous studies indicated that PARN can regulate the steady-state 
levels of ARE-containing mRNAs, such as p53 and c-myc, by indirect association to their 
transcripts under non-stress conditions (Devany et al., 2013). To examine the possible 
role of Ago-2 in recruiting PARN deadenylase to its mRNA targets, RNA 
immunoprecipitation assays were performed using samples from HCT116 cells treated 
with either control or Ago-2 siRNA (Figure 27). Consistent with my previous results 
(Devany et al., 2013), using antibodies against PARN, the RIP assays showed that both 
p53 and c-myc mRNAs formed a complex with PARN in samples from control siRNA-
treated cells (Figure 27). Interestingly, siRNA-mediated knockdown of Ago-2 reduced 
the interaction of PARN with both p53 mRNA and myc mRNAs. To confirm these 
results, one student at Dr. Kleiman’s lab, Emral Devany, performed RNA pull-down 
assays using an in vitro transcribed biotinylated RNA carrying the p53 3’UTR sequence 
and NEs from HCT116 cells treated with Ago-2 or control siRNAs (personal 
communication, not shown). Supporting my results, her studies indicate that RNA 
encompassing p53 3’UTR pulled-down PARN from samples of control siRNA-treated 
cells, and this RNA-PARN interaction significantly decreased when samples from Ago-2 
siRNA-treated cells were used in the assay.  
  
77 
 
 
Figure 27. Ago-2 is required for the association of PARN to its target mRNAs 
under non-stress conditions. NEs from HCT116 cells treated with Ago-2/control 
siRNA were prepared after formaldehyde crosslinking. The extracts were 
immunoprecipitated with either antibodies against PARN or control IgG. The 
endogenous nuclear RNA immunoprecipitated was quantified by qRT-PCR using 
primers specific for p53 and myc gene. The qRT-PCR values were calculated 
from three independent samples. 
  
To rule out the possibility that the effect of depletion of Ago-2 on reducing PARN 
association with p53 mRNA 3’UTR is due to the cell-wide response to low levels of Ago-2 
expression, Emral Devany also performed RNA pull-down assays using an in vitro transcribed 
biotinylated RNA encompassing WT p53 3’UTR, NEs from HCT116 cells treated with Ago-2 
siRNA and increasing amounts of recombinant Ago-2. Interestingly, increasing amounts of 
recombinant Ago-2 in the incubation system increased the amounts of PARN detected in the p53 
3’UTR pull-down fraction (personal communication, not shown). Together, these results suggest 
siRNA: CTRL Ago-2      siRNA:  CTRL  Ago-2
0
0.5
1
1.5
2
2.5
0
0.5
1
1.5
2
fo
ld
 c
h
a
n
g
e
 o
f 
p
5
3
 m
R
N
A
in
 P
A
R
N
 IP
fo
ld
 c
h
a
n
g
e
 o
f 
m
y
c
m
R
N
A
in
 P
A
R
N
 IP
78 
 
that Ago-2 might play a critical role in PARN-mediated regulation of gene expression by 
recruiting PARN to its target mRNAs. 
 
PARN regulates p53 expression through not only ARE but also miRNA targeting 
site present in the 3’UTR of p53 mRNA. 
It is known that PARN is involved in ARE-mediated deadenylation (Korner and 
Wahle, 1997; Lai et al., 2003; Lin et al., 2007).  My studies have shown that Ago-2 
activates PARN deadenylase through direct protein interaction (Figures 22-25) and 
participates in recruiting PARN to some of its mRNA targets (Figure 27), suggesting that 
PARN might play a role not only in ARE- but also miRNA-mediated deadenylation. 
Supporting this, others have shown the functional overlapping of ARE- and miRNA-
mediated regulatory pathways (Bhattacharyya et al., 2006; Jing et al., 2005; Kim et al., 
2009). Interestingly, p53 mRNA contains both miRNA targeting sites (miR-504, miR-
125a/miR-125b, and miR25/miR30d) and AREs at its 3’UTR, and some of these signals 
overlapped as showed in Figure 28. To test whether both AREs and miRNA targeting 
sites are involved in the PARN-associated Ago-2-mediated regulation of p53 mRNA 
steady-state levels under non-stress conditions constructs were generated that have the 
luciferase gene under the control of WT p53 3’UTR or replacement mutants in AREs 
and/or miRNA targeting sequences that are in close proximity in the p53 3’UTR (Figure 
29). More specifically, I focused my studies on miR-504 (Hu et al., 2010; Le et al., 2009) 
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Figure 28. Sequence of p53 mRNA 3’UTR. miR-binding sites and AU-rich 
elements (AREs) are shown. miR-125b binding site (red) and miR-504 binding 
site are adjacent to an ARE (blue).   
CATTCTCCACTTCTTGTTCCCCACTGACAGCCTCCCACCCCCATCTCTCCCTCCCCTGCCATTTTGGGTTTTGGGTCTTTGAACC
CTTGCTTGCAATAGGTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGGGCTCCACTGAACAAGTTGGCCTGCA
CTGGTGTTTTGTTGTGGGGAGGAGGATGGGGAGTAGGACATACCAGCTTAGATTTTAAGGTTTTTACTGTGAGGGATGTTTGGG
AGATGTAAGAAATGTTCTTGCAGTTAAGGGTTAGTTTACAATCAGCCACATTCTAGGTAGGGGCCCACTTCACCGTACTAACCAG
GGAAGCTGTCCCTCACTGTTGAATTTTCTCTAACTTCAAGGCCCATATCTGTGAAATGCTGGCATTTGCACCTACCTCACAGAGT
GCATTGTGAGGGTTAATGAAATAATGTACATCTGGCCTTGAAACCACCTTTTATTACATGGGGTCTAGAACTTGACCCCCTTGAG
GGTGCTTGTTCCCTCTCCCTGTTGGTCGGTGGGTTGGTAGTTTCTACAGTTGGGCAGCTGGTTAGGTAGAGGGAGTTGTCAAGT
CTCTGCTGGCCCAGCCAAACCCTGTCTGACAACCTCTTGGTGAACCTTAGTACCTAAAAGGAAATCTCACCCCATCCCACACCC
TGGAGGATTTCATCTCTTGTATATGATGATCTGGATCCACCAAGACTTGTTTTATGCTCAGGGTCAATTTCTTTTTTCTTTTTTTTT
TTTTTTTTTCTTTTTCTTTGAGACTGGGTCTCGCTTTGTTGCCCAGGCTGGAGTGGAGTGGCGTGATCTTGGCTTACTGCAGCCT
TTGCCTCCCCGGCTCGAGCAGTCCTGCCTCAGCCTCCGGAGTAGCTGGGACCACAGGTTCATGCCACCATGGCCAGCCAACT
TTTGCATGTTTTGTAGAGATGGGGTCTCACAGTGTTGCCCAGGCTGGTCTCAAACTCCTGGGCTCAGGCGATCCACCTGTCTCA
GCCTCCCAGAGTGCTGGGATTACAATTGTGAGCCACCACGTCCAGCTGGAAGGGTCAACATCTTTTACATTCTGCAAGCACATC
TGCATTTTCACCCCACCCTTCCCCTCCTTCTCCCTTTTTATATCCCATTTTTATATCGATCTCTTATTTTACAATAAAACTTTGCTG
CCACCTGTGTGTCTGAGGGGTG
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and miR-125b (Le et al., 2009) that are located next to the ARE (Vilborg et al., 2009; 
Zou et al., 2006) in the p53 3′UTR that is important for PARN binding and PARN- 
mediated regulation of p53 mRNA steady-state levels (Figure 20; (Devany et al., 2013). 
Interestingly, the siRNA-mediated knockdown of PARN significantly increased the ratio 
of firefly/renilla luciferase activity from the constructs carrying the WT p53 3’UTR but 
the effect of PARN knockdown was completely abolished when the AREs (noARE), 
miRNA target site (nomiR) or both (noBOTH) signals are replaced by other sequences 
(Figure 30). Together, these results indicate that both regulatory signals at the p53 3’UTR 
are necessary for PARN-mediated regulation of p53 expression.  
 
 
 
 
Figure 29. Diagram of firefly luciferase reporter constructs with different 
3’UTR sequences from the p53 gene. Polyadenylation signals (PAS) are 
indicated.   
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Figure 30. Both miRNA targeting sites and AREs are critical for PARN-
mediated regulation of p53 expression. Constructs carrying the p53 3’UTR (p53) 
or ARE (noARE), miR-125b targeting site (nomiR) or both signals (noBOTH) 
replaced p53 3’UTR were transfected into HCT116 cells. Luciferase assays were 
done in cells treated with control or PARN siRNA. The ratio of the firefly/Renilla 
values obtained for each construct in PARN knockdown cells relative to control 
siRNA-treated cells are shown. The firefly/renilla values were calculated from three 
independent samples. Errors represent the SD derived from three independent 
experiments. 
 
Next, I examined whether PARN physically associates with p53 mRNA through 
ARE and/or miRNA targeting sites in the 3’UTR. First, several cell lines were used to 
test if ARE sequence present at the p53 mRNA 3’UTR is critical for the interaction of 
PARN with p53 mRNA. Consistent with my previous studies (Figure 20), the RIP assays 
indicated that PARN can form a complex with the luciferase mRNA carrying the 3’UTR 
of p53 and this is abolished when AREs are replaced by other sequences (Figure 31). 
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RKO/RKO-E6 and HCT116/HCT116 p53-/- cells showed similar ratios for the RIP 
assays with different constructs, indicating that the PARN-mediated regulation of p53 
expression and PARN binding to AREs are p53 independent.  
 
 
 
Figure 31. ARE sequences present in the 3′ UTR are involved in the interaction 
of PARN with p53 mRNA under non-stress conditions. RIP analysis of samples 
cells transfected with luciferase constructs carrying either the p53 3′ UTR (p53) or 
ARE-replaced p53 3′ UTR (noARE). Nuclear extracts were immunoprecipitated 
with either anti-PARN or IgG antibodies. The endogenous nuclear RNA 
immunoprecipitated with the antibodies was quantified by qRT-PCR using primers 
specific for the luciferase gene. The ratio of the fold change for p53/no-ARE RNA 
values obtained for each construct is shown. The qRT-PCR values were calculated 
from three independent samples. 
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Extending these studies, the RIP assays indicate that PARN cannot form a 
complex with the luciferase mRNAs carrying the 3’UTR of p53 with replaced sequences 
in the AREs or/and miRNA targeting sites (Figure 32). Importantly, the interaction of 
PARN with the luciferase mRNA carrying the 3’UTR of p53 is lost in HCT116 cells 
treated with Ago-2 siRNA, indicating that Ago-2 knockdown and the replacement of the 
3’UTR signals had a similar effect on the interaction of with p53 3’UTR. Together these 
results support the idea that miRNA-associated Ago-2 and ARE might be part of the 
same PARN-mediated regulatory pathway. Moreover, RNA pull-down assays using 
RNAs encompassing either WT p53 3’UTR or the mutant variants of p53 3’UTRs, and 
NEs from HCT116 cells showed that the RNA-PARN interaction depended on the 
presence of both the ARE sequence and miRNA targeting site (Figure 33). As expected, 
the interaction of Ago-2 with the RNA was not decreased by the replacement of the ARE.  
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Figure 32. Ago-2 expression and cis-acting signals present in the 3’UTR of 
p53 mRNA are involved in the association of PARN with p53 mRNA 3’UTR. 
RIP assays were performed using samples from HCT116 cells treated with Ago-
2/control siRNAs and transfected with the luciferase constructs described in 
Figure 29. 
 
Figure 33. Both ARE and miR-125b targeting signal at the 3’UTR are 
necessary for PARN to target at p53 mRNA. RNA pull-down assays were 
performed using biotinylated RNA carrying WT or signal replaced (noARE, 
nomiR, and noBOTH) 3’UTR of p53 and NEs from HCT116 cells. A 
representative pull-down reaction from three independent assays is shown. 
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PARN functionally interacts with miR-125b-associated Ago-2. 
Then I tested whether miRNAs play a role in the PARN-mediated regulation of 
p53 mRNA stability in the nucleus of human cells. I studied miRNAs, such as miR-504, 
miR-125b, and miR25/30d, that have been previously shown to have a target site in p53 
3’UTR and to downregulate p53 expression (Hu et al., 2010; Kumar et al., 2011; Le et 
al., 2009)). First, the effect of UV-treatment on the abundance of these miRNAs was 
determined in samples from HCT116 cells by qRT-PCR analysis of total and nuclear 
RNA samples. Consistent with previous reports (Le et al., 2009; Pothof et al., 2009; Tan 
et al., 2012), the total amount of each miRNA showed a change of different magnitude 
after DNA damage (Figure 34). Changes in the abundance of these miRNAs were also 
observed in the nuclear RNA samples in response to DNA damage. As described before 
(Kim et al., 2008), these results also showed the enrichment of miR-320 in nuclear 
fractions.  
To examine whether PARN associates with these miRNAs, nuclear lysates from 
HCT116 cells were immunoprecipitated with an antibody against PARN or control IgG 
followed by RT-qPCR detection of miRNAs. Interestingly, RIP assays indicate that under 
non-stress conditions miR125b was significantly enriched in PARN-IP (Figure 35). Both 
miR-30d and miR-504 also showed some association with PARN. Remarkably, all p53 
3’UTR targeting miRNAs show dramatic decrease in PARN association in response to 
UV-induced DNA damage, suggesting that PARN might have a critical role in miRNA- 
mediated downregulation of p53 expression under non-stress conditions. miR320, which 
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Figure 34. Abundance of p53 targeting miRNAs in response to UV 
irradiation. Nuclear and total RNAs from UV treated HCT116 cells were 
isolated and miRNA abundance was assessed by qRT-PCR using a specific kit for 
miRNA analysis.  
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does not target at p53 3’UTR, was used as control for binding specificity. These results 
are consistent with our previous report (Devany et al., 2013) that showed that p53 mRNA 
and p53 protein levels are regulated by PARN under non-stress conditions and are 
PARN- independent after UV treatment. 
To examine the role of miR-125b in PARN-mediated p53 mRNA decay HCT116 
cells were transfected with miR-125b inhibitor expression plasmid, which blocks 
endogenous miR-125b, or control plasmid and analyzed p53 mRNA steady-state levels. 
  
 
 
 
Figure 35. PARN association to different p53 targeting miRNAs is favored in 
non-stress conditions. RIP assays were performed as described in Material and 
Methods. Nuclear miRNAs immunoprecipitated were quantified by qRT-PCR. 
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In Figure 36, the functional knockdown of miR-125b showed an increase in p53 mRNA 
(upper panel) and protein levels (lower panel). A similar increase in both p53 mRNA and 
p53 expression was determined after PARN-knockdown (Devany et al., 2013). 
Importantly, as shown in Figure 37A, the functional inhibition of miR-125b elongated the 
poly(A) tail length of p53 mRNA (quantification is shown in Figure 37B), indicating 
miR-125b regulates p53 mRNA steady-state level through modulating its poly(A) tail 
length.  
 
 
 
Figure 36. Functional knockdown of miR-125b increases p53 mRNA and 
protein levels. Samples from HCT116 cells transfected with miR-125b inhibitor 
expression plasmids or control vectors were analyzed for p53 mRNA levels by 
qRT-PCR and for p53 protein levels by Western blot. 
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Figure 37. miR-125b regulates p53 mRNA poly(A) tail length. Nuclear RNAs 
from HCT116 cells transfected with miR-125b inhibitor expression/control 
vectors were reverse-transcribed using an oligo(dT)-anchor primer and amplified 
using an oligonucleotide that hybridizes within the 3’UTR of p53 mRNA. The 
products were separated on a non-denaturing PAGE and detected by ethidium 
bromide staining. An RT-PCR product from a non-PARN target gene (ACTIN 
exon 3–4) was used as a loading control. A representative PAGE from three 
independent assays is shown. Molecular weight standard (MWS, 100 base pair 
ladder from Promega) is also included. 
 
Then I tested whether miR-125b is involved in PARN association with p53 
mRNA. Nuclear lysates from HCT116 cells transfected with miR-125b inhibitor 
expression or control plasmids were used for miRNA-IP assays using PARN antibodies. 
The RIP assays showed that the functional expression of miR-125b increased the binding 
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of PARN to p53 mRNA (Figure 38). To further assess the regulatory function of miR-
125b in miRNA-mediated deadenylation, NEs from HCT116 cells transfected with miR-
125b inhibitor or control vectors were analyzed for deadenylation assays. These assays 
were performed using an in vitro transcribed, radiolabeled, capped and polyadenylated 
(A20) RNA encompassing the the WT p53 3’UTR (Figures 39A) and the mutants 
described in Figure 29 (Figures 39B). Importantly, samples from cells with function loss 
of miR-125b showed a decrease in the deadenylation of WT p53 3’UTR (Figure 39A), 
indicating miR-125b is important to promote miRNA-mediated deadenylation of p53 
mRNA. In Figure 39B, the deadenylation assays showed that the presence of the 
targeting sequence was important for this miR-125b-mediated deadenylation of p53.  
 
 
Figure 38. Functional loss of miR-125b attenuates p53 mRNA association with 
PARN. RIP assays were performed as described before, using NEs from HCT116 
cells transfected with miR-125b inhibitor expression plasmids or control vectors. 
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Figure 39. Functional knockdown of miR-125b inhibits deadenylation of p53 
mRNA. A) Deadenylation assays were performed NEs from HCT116 cells 
transfected with miR-125b inhibitor expression/control plasmids and a 
radiolabeled/polyadenylated RNA encompassing the p53 WT 3’UTR. Positions of 
the polyadenylated RNA (p53 3’UTR A20) and deadenylated product (p53 
3’UTR) are indicated. Numbers beneath gel lanes indicate relative deadenylation 
(RD). RD was calculated as [p53 3’UTR/(p53 3’UTR + p53 3’UTR A20)] x 100. 
Quantifications were done with Image J software. B) Regulatory signals at the 
3’UTR of p53 are important for deadenylation of p53 mRNA. Deadenylation 
assays were performed using NEs from HCT116 cells and 
radiolabeled/polyadenylated (A20) RNA encompassing WT or signal replaced 
(noARE, nomiR, and noBOTH) 3’UTRs of p53. Deadenylation reactions were 
analyzed as in Figure 24. 
  
miRNA inhibitor: CTRL  miR-125b      
-p53 3’UTR A20
-p53 3’UTR
RD:     1     0.75            
p53 3’UTR:   WT     noARE nomiR noBOTH
-p53 3’UTR A20
-p53 3’UTR
RD:     1        0.85       0.68        0.65      
A 
B
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DISCUSSION 
miRNA pathway was originally believed to act only in the cytoplasm. However, a 
growing number of evidence has shown that this pathway has also a nuclear component 
(Ohrt et al., 2008). Although it has been shown that nuclear miRISCs are involved in 
miRNA-mediated gene silencing in the nucleus (Nishi et al., 2013; Robb et al., 2005), the 
mechanism(s) underlying miRNA-mediated regulation of gene expression in the nucleus 
remain(s) to be elucidated. Two deadenylase complexes, CAF1/CCR4/NOT1 and Pan2-
Pan3, have been shown to facilitate cytoplasmic miRNA-mediated deadenylation in 
mammalian cells (Behm-Ansmant et al., 2006; Fabian et al., 2009; Piao et al., 2010), 
however, little is known about miRNA-mediated deadenylation in the nucleus. Here, my 
studies indicate that PARN deadenylase plays a critical role not only in ARE- but also in 
miRNA-mediated regulation of mRNA stability and, consequently, expression levels in 
the nucleus of mammalian cells. Consistent with this, biochemical evidence shows that 
PARN is a nuclear miRISC-associated deadenylase: both PARN and elements of miRISC 
were present in the nuclear fractions (Figure 21), PARN physically interacted with Ago-
2, a key a component of mammalian miRISC complex (Figures 22-23), and Ago-2 
activated PARN deadenylase activity (Figures 24-25). Extending these studies, I showed 
that PARN regulated the expression of one of its targets, p53, by interacting with not only 
ARE sequences but also miRNA targeting sites present in the 3’UTR of p53 mRNA 
(Figure 31-33). Furthermore, my results indicate that Ago-2 (Figure 27) and miR125b 
(Figure 38) facilitated the binding of PARN to the target p53 mRNA 3’UTR resulting in 
p53 mRNA poly(A) tail shortening and decrease in p53 transcript and protein levels. 
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Taken together, these results provide new insights into the nuclear function of miRISCs 
in the PARN-mediated regulation of deadenylation and gene expression.  
Previous work from Dr. Kleiman’s lab showed an alternative mechanism to 
regulate the expression levels of p53 based on the control of the steady-state levels of p53 
mRNA by PARN deadenylase under non-stress conditions (Devany et al., 2013). Based 
on the results presented here, I propose a model in which, under non-stress conditions, 
miRISC targets p53 mRNA through miR-125b resulting in the recruitment of PARN 
deadenylase by its direct interaction with miRISC major component Ago-2. The binding 
of PARN to these protein complexes activates its deadenylation activity resulting in p53 
mRNA decay and control of gene expression (Figure 40). The steady-state levels of other 
PARN target mRNAs, such as c-myc, c-fos, c-jun, and transcripts in the p53 and 
BARD1/BRCA1 pathways, might be regulated following a similar model. Although more 
work is necessary to determine the identity of the ARE-BPs involved in PARN-mediated 
degradation of p53 mRNA, these results indicate that ARE sequences are also involved in 
this process. Most of the known PARN-associated ARE-BPs, such as tristetraprolin 
(TTP) and KH-type splicing regulatory protein (KSRP), are involved in the deadenylation 
of ARE-containing mRNAs followed by the recruitment of the exosome (Cevher and 
Kleiman, 2010).  
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Figure 40. Model of multicomponent complexes required for regulation of 
p53 mRNA steady-state levels by nuclear PARN deadenylase in different 
cellular conditions. Cooperation of ARE-BPs, miRNAs, miRISC, PARN 
deadenylase and exosome is essential for the regulation of p53 mRNA stability in 
different cellular conditions. The recruitment of the ARE-BPs to the ARE 
sequence and/or the targeting of miR-125b-loaded miRISC complexes to the most 
proximal site to the ARE sequence assist in the recruitment of PARN deadenylase 
to the target mRNA. Changes in the ARE-BPs bound to the 3’UTR, miRNA 
abundance and Ago-2 cellular localization might signal the DDR. miRNA 
targeting sites present in p53 mRNA 3’UTR are shown in different colors (miR-
25 gray, miR-30d purple, miR-125b red, miR-504 orange).   
95 
 
Regulation of mRNA stability by sequences in the UTR of the mRNA is not a 
new concept. The typical scenario is the control of mRNA stability by 3’UTR sequences 
and the recruiting of diverse protein regulators. The implication of both cis-acting RNA 
elements and trans-acting protein factors increases the complexity of the regulation of 
gene expression. The studies presented in this dissertation indicate that the presence of 
both miRNA binding sites and AREs at the 3’UTR is critical for PARN-dependent 
regulation of mRNA deadenylation and stability. However, further studies are necessary 
to determine whether the proximity of these regulatory elements is important in this 
PARN-associated regulatory pathway. Although the exact contribution of miRNAs, 
miRISC, AREs and ARE-BPs to mRNA decay has not been elucidated yet, recent studies 
have described a functional overlap between ARE- and miRNA-mediated mRNA 
turnover pathways (Zhang et al., 2010). It has been described that miRNAs can 
functionally interact with ARE-BPs, and that Dicer and Ago are required for ARE-
mediated decay (Jing et al., 2005). For example, it has been shown that HuR can bind to 
AREs present in c-myc 3'UTR at a site proximal to that recognized by let-7 miRNA, 
facilitating the targeting of let-7-loaded miRISC and mediating the reduction of c-Myc 
mRNA levels (Kim et al., 2009). Another example is the functional interaction of ARE-
BP TTP and miRISC that results in the recruitment of the deadenylase and the exosome 
for tumor necrosis factor-α mRNA degradation (Jing et al., 2005). Interestingly, 20% of 
PARN mRNA targets in the p53 signaling pathway showed both miRNA target sites and 
an ARE in their 3’UTRs (Table 1). Some of my studies work indicates that PARN 
regulates the stability of short-lived ARE-containing mRNAs involved in the control of 
cell growth, DDR and differentiation, and keeps their levels low (Cevher et al., 2010; 
96 
 
Devany et al., 2013). PARN deadenylase is recruited to ARE sequences by ARE-BPs 
KSRP (Gherzi et al., 2004), CUG-BP (Moraes et al., 2006) or TTP (Korner and Wahle, 
1997; Lai et al., 2003). It is possible that miRNA-loaded miRISC might contribute with 
one of these ARE-BPs to the recruitment of PARN to its target mRNAs.  
The results presented in this dissertation also indicate that Ago-2 shuttles from the 
nucleus to the cytoplasmic compartment upon DNA-damaging conditions (Figure 21), 
and this might contribute to the UV-induced increase in p53 expression levels. The UV-
induced decrease of nuclear Ago-2, which is involved in the recruitment of PARN to p53 
mRNA and activation of its deadenylase activity, might explain my observation that the 
UV-induced changes in p53 expression are PARN-independent (Devany et al., 2013). 
Furthermore, the UV-induced changes in miRNA-expression profiles (Pothof et al., 
2009) might also contribute to the previously described PARN-independent changes in 
p53 expression levels (Devany et al., 2013), providing an additional layer of gene 
regulation and a new dimension to DDR. The UV-induced changes in the binding of 
different ARE-BPs to the 3’UTRs of the PARN target mRNAs might also influence the 
resulting expression levels. For example, it has been shown that after UV treatment ARE-
BP Human Antigen R (HuR) binds to AREs, resulting in the dissociation of TTP and 
KSRP from ARE-containing mRNAs and the up-regulation of genes involved in DDR 
(Cevher and Kleiman, 2010).  
Taken together, my characterization of PARN-dependent regulatory pathways 
indicates a novel nuclear function of miRISC in controlling gene expression of different 
genes in different cellular conditions. The study presented in this dissertation addresses 
the mechanism behind miRNA-dependent control of deadenylation in the nucleus, 
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showing the functional interplay among PARN deadenylase, the AREs in the 3’UTR, 
miRNA abundance and Ago-2 cellular localization. My studies also provide new insights 
on regulatory mechanisms in the p53 pathway. While most of the studies on the 
expression of genes involved in stress response pathways have traditionally focused on 
transcription as a major regulator, it has recently become apparent that the 
posttranscriptional control of mRNA steady-state levels may play an equally important 
role. The mechanism(s) behind the regulation of p53 mRNA levels under non-stressed as 
well as DNA-damaging conditions has(ve) not been well characterized. My results 
indicate that PARN deadenylase keeps p53 levels low in non-stress conditions by 
interacting with both AREs and miRNA targeting sites in the 3’UTR and destabilizing the 
p53 mRNA. Importantly, these studies support the functional overlap between ARE- and 
miRNA-mediated mRNA turnover pathways, increasing the complexity of the signaling 
present in the 3’UTR of different genes. This is consistent with the idea that cell-specific 
3′ processing profiles, and hence gene expression patterns, depends on the complexity of 
the signaling in the 3’UTR of the genes and the functional/dynamic interaction of the 3′ 
processing machinery and the DNA damage response/tumor suppression factors, 
providing functional connection between mRNA processing and cancer subtypes, and 
proposing new approaches in the design of new cancer therapies. 
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CHAPTER V 
NUCLEOLIN REGULATES PARN-DEPENDENT DEADENYLATION  
IN DIFFERENT CONDITIONS  
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INTRODUCTION 
Nucleolin is a highly conserved, multifunctional RNA binding protein (RBP) 
implicated in several cellular processes, such as chromatin remodeling, rRNA synthesis, 
mRNA processing, ribosome assembly, and nucleo-cytoplasmic transport (Angelov et al., 
2006; Ginisty et al., 1998; Hovanessian et al., 2010; Turner et al., 2009). Elevated levels 
of nucleolin are found in highly proliferative cells including a variety of tumors. 
Nucleolin is primarily located in the nucleolus but it is also found in other nuclear regions 
as well as in cytoplasm and plasma membrane (Borer et al., 1989; Ginisty et al., 1999). 
Nucleolin has RNA- and p53-binding properties (Serin et al., 1997; Srivastava and 
Pollard, 1999; Tajrishi et al., 2011; Tuteja and Tuteja, 1998), and can control gene 
expression by regulating mRNA stability and modulating the p53 signaling pathway 
(Abdelmohsen and Gorospe, 2012; Abdelmohsen et al., 2011; Bhatt et al., 2012; Chen et 
al., 2012; Daniely et al., 2002; Saxena et al., 2006; Takagi et al., 2005; Willimott and 
Wagner, 2010). For example, nucleolin modulates gene expression by direct binding to 
the untranslated regions (UTRs) of its target mRNAs resulting in a change of mRNA 
stability or translation level. Nucleolin can also control gene expression by modulating 
the p53 signaling pathway indirectly through protein-protein interactions. For example, it 
has been shown that the N-terminus of nucleolin associates with p53-antagonist Hdm2 in 
hyperproliferative cells to stabilize p53 protein and causes p53-mediated apoptosis (Bhatt 
et al., 2012).  
Most of the nucleolin target mRNAs are from stress-responsive genes and from 
genes whose expression is affected in disease, such as Alzheimer’s, cancer and 
inflammation. Some of nucleolin target mRNAs include antiapoptotic factor bcl-2 
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(Ishimaru et al., 2010; Otake et al., 2007; Willimott and Wagner, 2010), amyloid 
(Rajagopalan et al., 1998), JNK-mediated interleukin 2 (Chen et al., 2000) -globin 
(Jiang et al., 2006), tumor suppressor p53 (Takagi et al., 2005), potent pro-survival 
protein Akt1 (Abdelmohsen et al., 2011), and the growth arrest- and DNA damage 
inducible 45 protein (Gadd45α; (Zhang et al., 2006). Most of them bear AU-rich 
elements (AREs) or G-rich elements at their UTRs (reviewed by (Abdelmohsen and 
Gorospe, 2012). Nucleolin has been demonstrated to either increase or decrease the 
stability of the target mRNAs. For example, during DDR, nucleolin can stabilize the 
antiapoptotic mRNA bcl-XL by interacting with the AREs in their 3’UTR and protecting 
the poly(A) tail by association with poly(A) binding protein (PABP; (Zhang et al., 2008) 
and inhibit p53 mRNA translation by interacting with the 5’UTR (Chen et al., 2012; 
Takagi et al., 2005). Recently, transcriptome-wide analyses revealed that nucleolin 
enhances translation of mRNA with G-rich motif (Abdelmohsen et al., 2011). 
Interestingly, nucleolin’s expression, subcellular localization and post-translational 
modification are linked to its role as an RNA-binding stress responsive protein (Aoki et 
al., 2002; Daniely et al., 2002; Ginisty et al., 1998; Gorospe et al., 2011; Grinstein and 
Wernet, 2007; Kim et al., 2005; Masuda et al., 2009; Rickards et al., 2007). Therefore, it 
has been suggested a role for nucleolin in the regulation of mRNA stability of different 
target genes upon DNA damage, providing multiple levels of differential regulation of 
gene expression: 
It has been shown that nucleolin binds to p53 mRNA at a 5’UTR and 3’UTR 
base-pairing region in unstressed cells resulting in the repression of p53 mRNA 
translation (Chen et al., 2012). After DNA damage and stress stimulation, RPL26 is 
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recruited to this double-stranded RNA structure occupied by nucleolin forming nucleolin-
RPL26 heterodimers and enhancing the translation of p53 mRNA. However, whether 
nucleolin associates with AREs present in the 3’UTR of p53 mRNA and affects p53 
mRNA stability has not been tested. A recent report has shown that nucleolin mediates 
microRNA (miRNA)-directed deadenylation of the colony stimulating factor-1 (CSF-1) 
mRNA by binding factors from the miRNA-induced silencing complex (miRISC), such 
as Argonaute-2 (Ago-2) and cytoplasmic poly(A) binding protein 1 (PABPC-1) (Woo et 
al., 2013). Interestingly, the nucleolin/Ago2/PABPC-1 complex formation requires ARE 
regulatory elements present on the CSF-1 mRNA 3’UTR, supporting the functional 
interplay between miRNA- and ARE-mediated regulation of mRNA stability discussed in 
Chapter IV. 
Nucleolin can be phosphorylated by numerous kinases. Changes in the 
phosphorylation of nucleolin play a role in several critical cellular processes, such as cell 
growth, proliferation, cell cycle arrest, apoptosis as well as DNA damage response 
(DDR) (Daniely et al., 2002; De et al., 2006; Ishimaru et al., 2010; Kim et al., 2005; 
Nalabothula et al., 2010; Saxena et al., 2006; Storck et al., 2007; Takagi et al., 2005; 
Yang et al., 2009; Yang et al., 2002). Nucleolin is highly phosphorylated at the N-
terminus by two major kinases: interphase casein kinase II (CKII) and mitotic cyclin-
dependent kinase (Cdk/Cdc2) (Schneider et al., 1986; Warrener and Petryshyn, 1991). 
CKII-mediated phosphorylation of several cytosolic and nuclear substrates, including 
nucleolin, appears to be important for the regulation of cell growth. The extensive 
phosphorylation of nucleolin by CKII that occurs during interphase suggests that 
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phosphorylation may be a mechanism for regulating nucleolin function during the cell 
cycle.  
Nucleolin has distinct domains: the acidic N-terminus, which is highly 
phosphorylated by CKII and Cdks and contains the bipartite nuclear localization signal 
(NLS); four central RNA binding Domains (RBDs) that confer RNA-binding specificity, 
and the C-terminal Glycine-Arginine Rich (GAR) domain that exhibits helicase activity 
and is involved in many protein interactions including PABP and p53 (Figure 43; Tuteja 
and Tuteja, 1998; Ginisty et al., 1999; Srivastava and Pollard, 1999; Daniely et al., 2002; 
(Bhatt et al., 2012; Daniely et al., 2002; Ginisty et al., 1999; Srivastava and Pollard, 
1999; Tuteja and Tuteja, 1998; Zhang et al., 2008). Our collaborator, Dr. Saxena 
(Brooklyn College, CUNY), has engineered a novel system with tet-off promoter in 
human NARF6 cells to express 3xFlag-tagged WT-nucleolin or the phospho-variant 
6/S*A-nucleolin. In the phospho-variant nucleolin, six consensus CK2 phosphorylation 
sites were mutated from serine to alanine (Figure 41). The Tet-off promoter system 
allows nucleolin variants expression after removal of doxycycline (Dx) from the culture 
medium. The 6/S*A-nucleolin was tested deficient in phosphorylation by Dr. Saxena Lab 
(unpublished data kindly provided by Dr. Saxena). They also showed that although both 
phospho-variants of nucleolin increase p53 protein levels in unstressed cells, a greater 
increase in p53 is evident with 6/S*A expression. Interestingly, 6/S*A expression inhibits 
cell proliferation, probably due to increased p53 levels (Dr. Saxena personal 
communication). These differential effects on p53 induction and cell proliferation suggest 
a role for nucleolin phosphorylation in regulating gene expression of different target 
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genes in the p53 pathway. Thus, these inducible cell lines are valuable tools to facilitate 
studies and testing the role of nucleolin in gene regulation during the DDR. 
 
 
 
 
 
 
 
 
Figure 41. Modular structure of Nucleolin protein (WT and 6/S*A), 
indicating the positions of principal domains. The six consensus CK2 sites 
(serine residues) mutated to alanine in phospho-mutant construct-6/S*A are 
denoted by asterisks. 
 
 
Based on these studies, in this chapter I propose to dissect nucleolin’s role in 
governing mRNA stability of diverse target genes involved in DDR, and also provide 
mechanistic insights about the role of nucleolin phosphorylation in DDR. The specific 
hypothesis is that nucleolin interacts with mRNA 3’ processing factors and regulates the 
mRNA stability of genes involved either in the DNA repair or apoptotic response during 
the DDR. The working model is that nucleolin regulates stability of ARE-containing 
mRNAs by recruiting PARN deadenylase into its target mRNAs, such as p53 mRNA, 
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and these functions are modified by nucleolin phosphorylation state. Preliminary studies 
from Dr. Saxena’s lab indicate that cells expressing 6/S*A-nucleolin show increased 
levels of p53 expression in non-stress conditions, suggesting that the expression of this 
nucleolin phospho-variant mimics stress conditions. They also showed that 
nucleolin/PARN interaction increases after UV treatment, and this increase is abolished 
in samples expressing the nucleolin phospho-variant (not shown). Interestingly, my 
studies show that both nucleolin-WT and 6/S*A can interact directly with N-terminal 
domain of PARN in in vitro assays. The expression of WT nucleolin is necessary for the 
UV-induced activation of deadenylation, and this activation is abolished by the 
expression of 6/S*A nucleolin, suggesting that active dephosphorylation of nucleolin 
might be necessary for the activation of PARN deadenylation during DDR. Nucleolin 
interacts with the 3’UTR of one of PARN substrates, the p53 mRNA, under non-stress 
conditions in an AU-rich element (ARE)-dependent manner. Nucleolin phosphorylation 
affects its association with p53 mRNA both before and after UV treatment. Together 
these results indicate that the functional interaction of nucleolin with PARN deadenylase 
might provide a molecular mechanism for the rapid response to DNA damage allowing 
changes in the stability of different mRNAs, and this response might be regulated by 
nucleolin phosphorylation.  
RESULTS 
Preliminary data from Dr. Saxena’s lab showed that nucleolin/PARN interaction 
increases after UV treatment, and this increase is abolished in samples expressing the 
nucleolin phospho-variant (not shown). Extending those studies, I first tested whether 
nucleolin interacts directly with PARN.  Pull-down assays were performed using both 
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Flag-tagged nucleolin phospho-variants purified from NARF6 cells and different His-
PARN derivatives (Figure 42). The results indicated that PARN can interact directly with 
both WT- and 6/S*A-nucleolin, and that the N-terminal domain, which contains the 
nuclease activity and is responsible for cap-binding properties of PARN (Martinez et al., 
2001), is important for this interaction (Figure 42). Together these results indicate that 
both nucleolin phospho-variants can interact with the N-terminal domain of PARN. This 
suggests that the decrease in the UV-induced formation of the nucleolin/PARN complex 
in cells expressing 6/S*A variant observed by Dr. Saxena’s lab might be due the need of 
active dephosphorylation or other factors for the complex formation.  
 
Figure 42. Nucleolin directly interacts with N-terminal domain of PARN. 
Different His-PARN derivatives (FL: full-length, CTD: carboxyl-terminal 
domain, NTD: amino-terminal domain) were immobilized on nickel beads and 
incubated with WT or 6/S*A mutant nucleolin. Bound proteins were eluted, 
resolved by SDS-PAGE and detected with anti-nucleolin antibodies. 5% of Flag-
tagged nucleolin is shown as input.  
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To test the role of nucleolin in PARN-mediated deadenylation, in vitro 
reconstituted deadenylation assays were performed using radiolabeled L3(A30) RNA  
substrate to monitor the reaction, limiting amounts of recombinant His-PARN and 
increasing amounts of either WT-nucleolin or 6/S*A-nucleolin. As previously shown, 
increasing amounts of PARN deadenylase resulted in an increase of RNA substrate 
deadenylation (Figure 43, lanes 2-5). Importantly, only increasing amounts of purified 
Flag-tagged WT nucleolin can induce deadenylation in a reaction using a limited amount  
 
Figure 43. WT-nucleolin but not the 6/S*A phospho-variant activates PARN 
deadenylase activity. Deadenylation assays were performed in the presence of 
radiolabeled capped L3(A30) RNA substrate as described (Cevher et al., 2010) 
using different concentrations of His-PARN and increasing amounts of either 
Flag-WT-NCL or Flag-6/S*A-NCL. Positions of the polyadenylated RNA 
L3(A30) and the L3 deadenylated product are indicated. Numbers beneath gel lane 
indicate relative deadenylation (RD), which was calculated as [L3 
fragment/(L3(A30) + L3 fragment)] x 100. Quantifications were done with Image 
J software.   
Flag-Nucleolin:   - - - - -
His-PARN:     - 0.75   1.5      3   7.5    0.75  0.75   0.75  0.75  0.75   0.75   0.75   0.75   ng
Flag-6/S*A                     Flag-WT
-L3A30
-L3
Relative
Deadenylation:       8.1     11.2     22.5    28.2    37.5  12.3   14.5    15.7    13.5   27.7   35.6      45.9   58.3
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of His-PARN in a cell-free assay, suggesting that this is a transactivation-independent 
function of nucleolin. PARN-mediated deadenylation was enhanced up to 5.2 folds in the 
presence of WT-nucleolin (compare lane 2 and lane 10-13). The addition of Flag-tagged  
6/S*A-nucleolin did not have an effect on the deadenylation reaction (lanes 6-9). None of 
the phosphor-varinats were able to deadenylate the substrate in the absence of His-PARN 
(not shown). These results suggested that nucleolin is an activator of PARN deadenylase 
activity and nucleolin phosphorylation is necessary for this activation.  
Extending these studies, the role of nucleolin in deadenylation was tested using 
nuclear extracts (NEs) from cells expressing nucleolin-variants treated with either UV 
irradiation or Isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce ARF/p53 
expression. NEs from those cells were assayed for deadenylation activity using a 
radiolabeled L3(A30) RNA substrate. As described in previous studies (Cevher and 
Kleiman, 2010; Devany et al., 2013), Figure 44A shows that deadenylation activity in 
NEs of cells expressing WT-nucleolin increased significantly (up to 3.3 folds) after UV 
treatment (compare lanes 2 and 3). Interestingly, UV-induced activation of deadenylation 
was abolished in samples from cells expressing 6/S*A-nucleolin (compare lanes 5 and 6). 
As cells expressing 6/S*A-nucleolin show increased expression of p53 in non-stress 
conditions (information kindly provided by Dr. Saxena’s) and previous studies from Dr. 
Kleiman’s lab showed that p53 is an activator of PARN deadenylase activity (Devany et 
al., 2013), I decided to test whether p53 expression is sufficient to activate deadenylation. 
Interestingly, the IPTG-induced expression of p53 enhanced deadenylation to a similar 
level to that observed in samples from cells expressing WT-nucleolin treated with UV 
irradiation (compare lanes 1 to 3). These results suggest that deadenylation can be 
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activated by the induction of p53 expression in either DNA damage or oncogenic stimuli 
conditions. Importantly, IPTG treatment induced deadenylation in samples from cells 
expressing 6/S*A– nucleolin (compare lanes 1 to 4). Together, these results indicate that  
 
 
 
Figure 44. Nucleolin phosphorylation is necessary for deadenylation 
activation upon UV-induced but not in the oncogenic stimuli. A) NEs prepared 
from cells expressing nucleolin phospho-variants treated with/without UV 
irradiation (40 Jm
-2
) were prepared 2 h post-treatment and analyzed for 
deadenylation. Alternatively, cells were treated with 1.5 mM IPTG for 24 h to 
induce ARF/p53 expression. Positions of the polyadenylated RNA L3(A30) and 
the L3 deadenylated product are indicated. Numbers beneath gel lane indicate 
relative deadenylation: [L3 fragment/(L3(A30)+ L3 fragment)] x 100. 
Quantifications were done with Image J software. B) The bar graph shows the 
ratio of deadenylation in UV- or IPTG-treated cells relative to non-stress 
conditions.  
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nucleolin phosphorylation is necessary for deadenylation activation upon UV-induced 
DNA damage but not in the oncogenic stimuli (Figure 44B), suggesting that (a) 
mechanism(s) other than p53-induced activation of the deadenylation is involved in this 
response. 
My results indicate that the RNA binding protein nucleolin binds directly to 
PARN deadenylase resulting in the activation of its activity. To further analyze whether 
nucleolin plays a role in PARN-mediated regulation of mRNA stability I first tested the 
binding of nucleolin to one of PARN mRNA targets, the p53 mRNA (Devany et al., 
2013). The binding of nucleolin to the p53 mRNA was determined by RNA 
immunoprecipitation (RIP) assays using antibodies against nucleolin. RIP assays showed 
that p53 mRNA can form a complex with nucleolin under non-stress conditions in 
samples from cross-linked HeLa cells (Figure 45A), suggesting that nucleolin might 
regulate p53 mRNA stability by its association to PARN deadenylase and the 3’UTR of 
p53. This result is consistent with a model proposed by a recent report that nucleolin 
homodimer binds to p53 mRNA in unstressed cells resulting in the repression p53 
translation; while RPL26 disrupts the nucleolin homodimer and forms nucleolin-PRL26 
heterodimers resulting in p53 induction after DNA damage, (Chen et al., 2012). As 
nucleolin has been shown to associate with its target mRNAs through ARE regulatory 
elements in the 3’UTR (Sengupta et al., 2004) and miR targeting sequences (Woo et al., 
2013), I tested whether these cis-acting elements present in the p53 3’UTR are also 
important for nucleolin association with the mRNA. RNA pull-down assays were 
performed using with in vitro transcribed biotinylated RNAs, either with sequences of the 
p53 3′UTR or ARE/miRNA-replaced p53 3′ UTR, and NEs from RKO cells. RNA-pull   
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Figure 45. Nucleolin interacts with the 3’UTR of p53 mRNA under non-stress 
conditions in an ARE-dependent manner. A) Nucleolin can interact with 
endogenous p53 mRNA under non-stress conditions. HeLa cells were treated with 
formaldehyde to generate protein-RNA cross-links, then the samples were sheared 
by sonication followed by incubation with either anti-nucleolin or IgG antibodies. 
The endogenous nuclear RNA immunoprecipitated with the antibodies was 
quantified by qRT-PCR using primers specific for p53 gene. The qRT-PCR 
values were calculated from three independent samples. Input indicates samples 
before RIP. B) Nucleolin interacts with the p53 3’UTR in an ARE-dependent 
manner. RNA-pull down assays were performed using NEs from RKO cells and 
biotinylated RNA of either p53 or p53 mutant 3’UTRs [no-ARE: AU-rich 
element replaced; no-miR: miR504/miR125-b targeting sites replaced].  
 
down assays showed that the replacement of an ARE regulatory sequence in the p53 
3’UTR abolished nucleolin binding to p53 mRNA (Figure 45B). Interestingly, the 
replacement of miR-504/miR-125b targeting site also decreased the nucleolin’s 
association to the p53 mRNA. Together, these data indicates that nucleolin interacts with 
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the 3’UTR of p53 mRNA under non-stress conditions and that the presence of the cis-
acting regulatory sequences ARE and miR-504/miR-125b targeting sites at the 3’UTR of 
p53 mRNA are important for the RNA-nucleolin interaction. Interestingly, I showed in 
Chapter IV that PARN regulates the stability of p53 mRNA by interacting with not only 
ARE sequences but also miR-504/miR-125b targeting sites present in the 3’UTR of p53 
mRNA (Figures 32-33), supporting the idea that nucleolin and PARN functional 
interaction over the regulation of p53 mRNA stability under non-stress conditions.  
Next, I tested whether phosphorylation of nucleolin affect its association with p53 
mRNA. RIP assays were performed using Flag antibodies and samples from NARF cells 
expressing different phospho-variants of nucleolin treated with or without UV irradiation. 
RIP assays showed that (Figure 46). Upon UV-induced DNA damage, both WT- and 
6/S*A-nucleolin showed an increase in their association with p53 mRNA. However, p53 
mRNA showed stronger interaction with WT-nucleolin than with the 6/S*A-nucleolin 
phospho-variant, indicating that nucleolin phosphorylation affects nucleolin association 
with p53 mRNA.  
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Figure 46. Nucleolin phosphorylation affects its association to p53 mRNA. A) 
RIP assays of samples from NARF cells expressing the WT or 6/S*A nucleolin 
phospho-variants were performed as before using anti-Flag antibodies. The 
nuclear RNA in immunoprecipitated was quantified by qRT-PCR using primers 
specific for p53 gene. B) The bar graph shows the ratio of the fold change for UV-
treated/non-stress RNA values in nucleolin phospho-variants. 
 
DISCUSSION 
The post-transcriptional fate of mRNAs could be affected by many factors. RNA 
binding proteins are believed to play a fundamental role in the recognition of mRNA 
transcripts and regulating the recruitment of other trans-acting factors and/or factors that 
modulate the poly(A) tail, such as deadenylases and poly(A) binding proteins. The 
specific sequences that any RNA binding protein recognizes on its target transcripts and 
the location relative to other elements are of vital importance for regulation of gene 
expression. Diverse mRNA isoforms carrying different arrangement of regulatory signals 
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can be generated and dramatically alter mRNA stability and/or translation, hence gene 
expression. The RNA binding protein nucleolin has been shown to recognize the ARE 
signal at the 3’UTR of several mRNA targets and regulate their stability (Sengupta et al., 
2004). However, whether nucleolin plays a role in modulating p53 mRNA steady-state 
levels through its ARE element has not been tested. Previous studies have shown that 
PARN deadenylase is recruited to the p53 mRNA under non-stress conditions (Devany et 
al., 2013), however, the RNA-binding protein(s) necessary to recruit the active 
deadenylase to its mRNA substrates leading to mRNA deadenylation and degradation 
was not identified. Here my studies indicate that nucleolin binds the N-terminal domain 
of PARN deadenylase (Figure 42) and both of them bind to the same ARE element 
present in the p53 3’UTR (Figure 45; (Devany et al., 2013)). The PARN/nucleolin 
interaction resulted in the activation of PARN deadenylase activity (Figures 43-44). The 
results also indicate that the phosphorylation state of nucleolin is critical for the 
PARN/nucleolin functional interaction (Figures 43-44) and for nucleolin binding to p53 
mRNA (Figure 46). Together these results indicate that nucleolin is one of the RNA 
binding proteins that recruit PARN deadenylase to the tumor suppressor p53 mRNA, 
representing a novel regulatory mechanism for p53 gene expression. 
While most of the studies on the expression of genes involved in stress response 
pathways have traditionally focused on transcription as a major regulator, it has recently 
become apparent that the posttranscriptional control of mRNA steady-state levels may 
play an equally important role. The mechanism(s) behind the regulation of p53 mRNA 
levels under non-stressed as well as DNA-damaging conditions has(ve) not been well 
characterized. The results presented here indicate that nucleolin recruits PARN 
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deadenylase to p53 mRNA keeping p53 levels low in non-stress conditions by interacting 
with AREs in the 3’UTR and destabilizing the p53 mRNA. It is possible that a similar 
mechanism is used to regulate the steady-state levels of other mRNAs, hence gene 
expression, in different conditions. Nucleolin has been implicated in many different 
cellular processes through the identification of its target transcripts. It has been shown 
that nucleolin participates in the control of the steady-state levels of ARE-containing 
mRNA targets by regulating their stability and translation. It has been shown that 
nucleolin is involved in the stabilization of bcl2 mRNA through its association with an 
ARE signal present in the 3’UTR of bcl2 transcript resulting in an increase of its 
expression (Sengupta et al., 2004). Another target of nucleolin is bcl-XL mRNA, which 
is stabilized by nucleolin association to its ARE in response to UVA irradiation (Zhang et 
al., 2008). However, nucleolin also contributes to the selective destabilization of some 
other mRNA targets. For example, nucleolin associates with the 3’UTR of amyloid 
precursor protein (APP) mRNA and enhances its degradation in response to stress 
(Westmark and Malter, 2001). Consistent with this, other ARE-BPs have also been 
shown to increase and decrease mRNA stability in a gene-specific manner. For example, 
HuR-elicited stabilization of target mRNA has been extensively documented: 
stabilization of ARE-containing mRNAs during UV irradiation (Wang et al., 2000), heat 
shock (Gallouzi et al., 2000), hypoxia (Levy et al., 1998) and energy depletion (Jeyaraj et 
al., 2005). HuR has also been shown to recruit miRNA-induced silencing complex 
(miRISC) miRISC to destabilize c-myc mRNA and repress its expression (Kim et al., 
2009).  
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It is a widespread strategy to regulate ARE-mediated mRNA decay by changing 
the phosphorylation state of RNA binding proteins resulting in changes in their ability to 
bind their target mRNAs. For example, the phosphorylation of tristetraprolin (TTP) by 
MAPKAP kinase 2 (MK2) reduces binding affinity of TTP for its target mRNA, such as 
tumor necrosis factor-α (TNF-α), Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and interleukin 2 (IL-2) (Chrestensen et al., 2004). The p38 pathway-
mediated phosphorylation of KSRP reduces its association to the ARE region at the 
3’UTR leading to the stabilization of its mRNA targets (Briata et al., 2005). On the 
contrary, HuR phosphorylation enhances its binding to target mRNAs (Lafarga et al., 
2009). Interestingly, consistent with the results shown in Figure 46, it has been reported 
that the RNA-binding activity of nucleolin is also affected by phosphorylation. Nucleolin 
is phosphorylated in response to DNA damage by stress-activated protein kinases 
(SAPK) p38, and this increases its association with a subset of stress responsive 
transcripts in a UV irradiation dose-dependent manner (Yang et al., 2002). The results 
presented here indicate that cells expressing the dephospho-variant of nucleolin show a 
decrease in nucleolin binding to p53 mRNA (Figure 46) and in PARN deadenylase 
activity (Figures 43-44), which might probably result in an increase in p53 mRNA levels 
and explain the increase in p53 protein expression observed by Dr. Saxena’s lab (personal 
communication).  
Interestingly, Woo et al. (2013) recently described a role for nucleolin in miRNA-
directed mRNA deadenylation. Nucleolin interacts with the miRISC component Ago2 
indirectly via RNA and induces deadenylation of CSF-1 mRNA. Interestingly, 
nucleolin/Ago2-mediated degradation of CSF-1 mRNA depends on the functional 
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overlapping of miRNA targeting sites and AREs located at the 3’UTR of the target 
transcript (Woo et al., 2013). The results shown in this dissertation also indicate that both 
ARE sequences and miR targeting sites are involved in nucleolin binding to the p53 
mRNA (Figure 45), suggesting that nucleolin might regulate mRNA deadenylation of 
different targets through a similar mechanism. Surprisingly, the studies presented in 
Chapter IV indicate that PARN can interact directly with Ago2 (Figure 23) and that 
regulates the stability of p53 mRNA by interacting with not only ARE sequences but also 
miR-504/miR-125b targeting sites present in the 3’UTR of p53 mRNA (Figures 32-33). 
Furthermore, my results indicate that Ago-2 (Figures 27 and 32) and miR-125b (Figure 
38) facilitated the binding of PARN to the target p53 mRNA 3’UTR resulting in p53 
mRNA poly(A) tail shortening and decrease in p53 transcript and protein levels. Further 
work is necessary to investigate whether the phosphorylation state of nucleolin, which is 
important for the activation of PARN deadenylase and association to p53 mRNA, has an 
effect on p53 mRNA decay under different cellular conditions.  
Together, these studies suggest a functional interplay among PARN deadenylase, 
the RNA binding protein nucleolin, ARE elements, miRNA targeting sites, miRNA-
loaded miRISC, and miRNA abundance; and address the molecular mechanism behind 
miRNA-mediated/ARE-directed deadenylation of p53 mRNA in the nucleus. The model 
proposed in this work also provides a molecular mechanism for the rapid response to 
DNA damage allowing changes in the stability of different mRNAs by regulating 
nucleolin phosphorylation.  
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The modulation of mRNA stability plays important roles in the regulation of gene 
expression. Many mechanisms and factors are implicated in this precise control of 
mRNA turnover, which is more complex than it was previously thought. PARN 
deadenylase is one of the important factors involved in these regulatory pathways. PARN 
has been involved in several important biological processes, such as oocyte maturation, 
early development, DNA damage response (DDR) and cell-cycle progression. The results 
presented in this dissertation indicate that PARN deadenylase is involved in an alternative 
mechanism to regulate of p53 expression levels under non-stress conditions. Moreover, 
my studies also show that the functional interaction of PARN with microRNA (miRNA)-
induced silencing complex contributes to the regulation of the stability of p53 mRNA 
(Figures 35-38). This data is innovative because it is the first description of PARN 
deadenylase function in miRNA-dependent control of mRNA decay. Importantly, this is 
also the first mechanistic report of miRNA-function in the nucleus, which has been 
traditionally believed to take place only in the cytoplasm.  
Previous studies have shown that PARN is implicated in AU-rich elements 
(ARE)-mediated deadenylation and that several ARE-binding proteins facilitate PARN 
access to its targets, ARE-containing mRNAs, resulting in PARN dependent 
deadenylation. In this dissertation, these studies have been extended showing that PARN 
deadenylase has a specific effect on the steady-state levels of mRNAs containing not only 
AREs but also miRNA target sites (Figures 10, 12-13, Table 1). More importantly, I 
found that miR-125b-loaded miRNA-induced silencing complex (miRISC) contributes to 
the specific recruitment of nuclear PARN to one of its targets, the tumor suppressor p53 
mRNA (Figure 38), and ARE-binding protein nucleolin associates to the ARE element 
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that overlaps miR-125b target site and regulates PARN deadenylase activity (Figures 45-
48), representing a novel regulatory mechanism for p53 gene expression.  
The studies presented in this dissertation are innovative because they are the first 
to address the mechanism behind miRNA-dependent control of deadenylation in the 
nucleus and the functional interplay among PARN deadenylase, the regulatory signals in 
the p53 3’UTR, ARE-binding proteins, miRNA abundance and Ago-2 cellular 
localization. Now, it is important to further elucidate the complete mechanism behind 
PARN-mediated regulation of its targets in different cellular responses. The following 
proposed studies might help to understand some aspects of the working model shown in 
this dissertation.   
1) Further characterization of the role of PARN deadenylase in the regulation of 
mRNA stability of genes containing overlapped AREs and miRNA target sites: 
In recent years, the mechanisms underlying the miRNA-mediated repression of 
target mRNAs have been extensively explored. miRISCs, which deliver miRNAs to their 
mRNA targets, regulate gene expression through post-transcriptional events either by 
mRNA degradation, translation inhibition, or a combination of both. In this dissertation, 
it has been shown that Ago-2, the core component of the miRISCs, interacts directly and 
can coexist in complexes with PARN resulting in the activation of its deadenyase activity 
(Figures 22-25), supporting the idea that Ago-2 is critical for miRNA-mediated poly(A) 
removal. It is known that Ago-2 associates to the other miRISCs components, such as the 
GW182 factor and cytoplasmic poly(A) binding protein 1 (PABPC1), that contribute to 
miRNA-directed deadenylation (Fabian et al., 2009; Jinek et al., 2010; Zekri et al., 2009). 
120 
 
GW182 protein is considered the link between miRISCs and deadenylases, and it is 
important for promoting poly(A) removal (Lazzaretti et al., 2009; Takimoto et al., 2009; 
Zipprich et al., 2009). The other critical component of the miRISC, PABPC1, has a 
bimodal effect on PARN deadenylase activity: it can either activate or inhibit PARN 
deadenylase depending on the salt concentration (Korner and Wahle, 1997). Interestingly, 
PABPC1 has been traditionally considered to localize only in the cytoplasmic 
compartment. However, recent studies have revealed a role of PABPC1 during mRNA 
biogenesis in the nucleus (Lemay et al., 2010). It is also possible that the nuclear poly(A) 
binding protein (PABPN) might be the one associated with nuclear miRISCs and 
involved in recruiting PARN to the poly(A) tail and allowing miRNA-mediated 
deadenylation. Whether GW182 and/or PABC1 associates with PARN and affects its 
deadenylase activity remains to be determined.  Therefore, the elucidation of the 
functional interactions between PARN and these factors involved might provide a 
dynamic picture of the molecular networks used to regulate gene expression in different 
cellular conditions. It is important to highlight that Ago-2 binds directly PARN 
deadenylase and that is sufficient to recruit PARN to its target mRNAs (Figures 23, 27, 
32), suggesting that PARN interaction with any of the other components of the miRISc 
might be regulatory.  
The results presented in this dissertation indicate that PARN regulates the stability 
of short-lived ARE-containing mRNAs implicated in the control of cell growth, DDR and 
differentiation, and keeps their levels low in non-stress conditions (Cevher et al., 2010; 
Devany et al., 2013). Interestingly, it has been shown that PARN deadenylase is recruited 
to ARE sequences by ARE-binding protein KH-type splicing regulatory protein 
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(KHSRP) (Gherzi et al., 2004), CUG binding protein (CUG-BP; (Moraes et al., 2006) or 
tristetraprolin (TTP; (Korner and Wahle, 1997; Lai et al., 2003). In this study, the 
possible role of RNA binding protein nucleolin in the PARN-mediated regulation of p53 
expression was examined. The data presented in this dissertation showed that nucleolin 
associates with p53 mRNA through an ARE element at the 3’ untranslated region 
(3’UTR), and its phosphorylation state affects both nucleolin targeting to p53 mRNA and 
PARN-dependent deadenylation (Figures 43-46). However, whether nucleolin and its 
phosphorylation state play a role in facilitating PARN recruitment to the target mRNA 
and promoting p53 mRNA degradation under non-stress conditions need to be further 
elucidated. It is also important to determine how nucleolin functional interaction with 
PARN changes during the DDR. It would be also important to study the possible 
regulatory effect on PARN deadenylase of other ARE-binding proteins, such as HuR and 
Wig-1, that have been shown to bind the p53 3’UTR at an ARE signal proximal to miR-
125b targeting site. 
Although the exact contribution of miRNAs, miRISC, AREs and ARE-BPs to 
mRNA decay has not been elucidated yet, recent studies have revealed a functional 
overlap between ARE- and miRNA-mediated mRNA turnover regulatory pathways 
(Zhang et al., 2010). For example, it has been shown that the functional interaction of 
ARE-binding protein TTP and miR-16-loaded miRISC results in the recruitment of the 
deadenylase and the exosome to tumor necrosis factor-α mRNA resulting in its 
degradation (Jing et al., 2005).  Another example is the binding of HuR to AREs present 
in c-myc 3'UTR at a site proximal to that recognized by let-7 miRNA, facilitating the 
targeting of miRISC and mediating the reduction of c-myc mRNA levels (Kim et al., 
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2009). The studies presented in this dissertation indicate that 20% of PARN mRNA 
targets in the p53 signaling pathway showed both miRNA target sites and an ARE in 
their 3’UTRs (Table 1). It has also been shown that the presence of both miRNA binding 
sites and AREs at the 3’UTR is critical for PARN-dependent regulation of mRNA 
deadenylation and stability (Figures 30-33 and 39).  However, further studies are 
necessary to determine whether the proximity of these regulatory elements is important in 
this PARN-associated regulatory pathway.  
2) Characterization of the role of mRNA 3’ processing in regulating p53 mRNA 
expression during DDR: 
p53 is an important tumor suppressor which is implicated in various cellular 
processes by regulating the expression of a large number of genes involved in DNA 
repair, cell cycle arrest, and apoptosis through transcription activation. Besides its well 
established role as a transcriptional regulator, p53 has also been described to have 
transactivation-independent functions, such as mediating expression of certain miRNAs 
(reviewed in (Takwi and Li, 2009) and regulating mRNA 3’ processing (Devany et al., 
2013). It is the most commonly mutated gene in human tumors, and the regulation of p53 
levels under different cellular conditions is critical. It is well established that in response 
to cellular stress signals, p53 protein accumulates as a result of the downregulation of 
Mdm2 levels, which acts as an E3 ligase targeting p53 for degradation under non-stress 
conditions.  
The results presented in this dissertation showed that p53 and p53 signaling 
pathway are specific targets of PARN deadenylase under non-stress conditions. However, 
after UV-induced DNA damage, the changes in both p53 mRNA and protein levels are 
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PARN independent (Figure 14), suggesting that other mechanisms are involved in the 
regulation of p53 expression during DDR. Interestingly, data presented in this 
dissertation indicate that after UV irradiation Ago-2 translocates to cytoplasm and the 
abundance of p53 mRNA targeting miRNAs decreases, such as miR-125b and miR-504 
(Figures 21 and 34). These observations suggest that when cells are under stressed 
conditions, changes in Ago-2 cellular localization and miRNA abundance might signal 
the DDR, leading to PARN dissociation from p53 mRNA. Since the regulation of p53 
expression in non-stress conditions requires the cooperation of miRISCs, ARE-binding 
proteins and PARN deadenylase, an intriguing possibility could be that the dynamic 
change in the interaction of different factors with the same region of p53 3’UTR results 
in the stabilization of p53 mRNA, leading to the p53 induction in response to DNA 
damage. 
HuR, an ubiquitously expressed ARE-binding protein that belongs to the Hu 
(ELAV) family, has been shown to bind an ARE element at p53 mRNA 3’UTR and 
increase p53 mRNA stability after stress (Zou et al., 2006). Importantly, a recent study 
described a combinatorial regulation of mRNA stability by HuR and miRNAs 
(Mukherjee et al., 2011). In that study it was shown that over 75% of mRNAs with 
miRNA binding sites also have HuR binding sites, and most of these signals are less than 
10 nt distance from each other. HuR has been shown to be involved in miRNA-mediated 
regulation of mRNAs stability by either a competitive or cooperative function. For 
example, it has been shown that HuR plays a role in recruiting let-7-loaded miRISC to 
repress c-myc expression (Kim et al., 2009). On the other hand, it has also been shown 
that upon stress conditions HuR can outcompete and relieve CAT-1 mRNA from miR-
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122-induced repression, leading to the stabilization of the mRNA in human liver cells 
(Bhattacharyya et al., 2006). As HuR recognizes the ARE sequence that overlaps with 
miR-125b targeting site in p53 mRNA upon DNA-damaging conditions, it is important to 
further investigate the potential functional overlapping of PARN/nucleolin-mediated 
inhibition of p53 expression under non-stress conditions and HuR-mediated induction of 
p53 expression upon DNA damage response. 
3) Determination of the mechanisms behind the PARN-mediated regulation of the 
steady-state levels of other target genes: 
PARN is one of the major mammalian deadenylases and is associated with a 
variety of important cellular processes through mediating the deadenylation of a specific 
subset of mRNAs. The data presented in this dissertation indicate that the mRNA levels 
of both housekeeping genes and ARE-containing genes are regulated by PARN 
deadenylase under different cellular conditions (Figure 10). As the tumor suppressors 
BARD1 (Cevher et al., 2010) and p53 (Devany et al., 2013) can activate PARN 
deadenylase, it is possible that malignant cells display altered levels of polyadenylation 
of specific mRNAs. In fact, increased expression of PARN has been detected in acute 
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML; (Maragozidis et al., 
2012), suggesting that the alteration of PARN deadenylase expression might be used as a 
potential biomarker for cancer cells. It has been shown that PARN is involved in the 
regulation of the stability of several cancer-related mRNAs, such as IL-8, Vascular 
endothelial growth factor (VEGF), c-myc, c-fos, c-jun, urokinase-type plasminogen 
activator (uPA) and TNF-α (Chou et al., 2006; Lai et al., 2003; Moraes et al., 2006; 
Suswam et al., 2008). This is consistent with the microarray results presented here: the 
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most affected genes by PARN depletion are p53-related genes that have been shown 
linked with cancerous growth and DNA repair activities. Interestingly, 20% of these 
PARN mRNA targets in the p53 signaling pathway showed both miRNA target sites and 
ARE in their 3’UTRs. The studies presented in this dissertation were carried out using 
p53 mRNA as a model to investigate the mechanism underlying PARN-dependent 
regulation of mRNA stability. Interestingly, like p53, both fos and myc mRNAs have 
proximal AREs and miRNAs targeting sites in their 3’UTRs. Besides the increase in c-
fos and c-myc mRNA levels in PARN-depleted cells in non-stress conditions were 
confirmed by qRT-PCR (Figures 10 and 13). More importantly, functional overlap 
between ARE-and miRNA-mediated regulatory pathways has been described to regulate 
c-myc mRNA stability and translation levels (Kim et al., 2009). As mentioned before, c-
myc expression is repressed by both miRNA let-7 and ARE-binding protein HuR, which 
binds to ARE present in c-myc 3'UTR at a site proximal to that recognized by let-7 
miRNA (Kim et al., 2009). However, whether PARN is the deadenylase mediating c-myc 
mRNA reduction through association with either let-7-loaded miRISC or HuR is not 
known. Together, these studies and the results presented in this dissertation suggest a 
possible role of PARN in regulating genes containing a conserved arrangement of signals 
in their 3’UTR, a miRNA targeting site overlapping or in close proximity to ARE 
regulatory signal. Together, future studies designed to test this hypothesis and the studies 
presented in this dissertation will serve as a valuable framework both for understanding 
these critical biological processes and for developing appropriate therapeutic approaches 
to a variety of disorders, including cancer. 
 
126 
 
 
 
 
 
 
 
CHAPTER VII 
EXPERIMENTAL PROCEDURES 
 
 
 
 
 
 
  
127 
 
Tissue culture methods - HeLa, HCT116, HCT116 p53-/- cell lines were cultured in 
Dulbecco’s modified Eagles medium (DMEM)-10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin antibiotic . RKO, RKO-E6 cell lines were cultured in Eagle's 
minimal essential medium (EMEM)-10% FBS and 1% penicillin/streptomycin antibiotic 
supplemented with 2 mM glutamine.  
DNA-damaging agents - 90% confluent cultures were exposed to UV and harvested at 
the indicated times. UV doses (40 J/m
2
) were delivered in two pulses using a stratlinker 
(Stratgene).  Prior to pulsing, medium was removed and replaced immediately after 
treatment. 
Knockdown expression of PARN or Ago-2 by siRNA - siRNAs specific for either 
human PARN or Ago-2 and the control siRNA used as non-silencing were obtained from 
Dharmacon RNA technologies.
 
Cells were grown in a 10-cm plate in complete 
DMEM/EMEM. At 50-60% confluence, the cells were transfected with 100 nM of 
PARN, Ago-2 or control siRNA and 60 µl of Lipofectamine
 
2000 (Invitrogen) according 
to the manufacturer’s protocol. After culturing the cells in antibiotic/FBS free medium 
for 8 h, medium was changed to complete medium. After additional 16 h, cells were 
transfected again and harvested for analysis 48 h after the initial transfection. To 
determine the specificity of siRNAs used protein levels were monitored.
  
miRNA inhibitor expression plasmid transfection – Either miR-125b inhibitor 
expression plasmid (HmiR-AN0096-AM03, GeneCopoeia) or control plasmid (AM03, 
GeneCopoeia) were were transfected into HCT116 cells. Cells were grown in a 10-cm 
plate in complete DMEM. At 50-60% confluence, the cells were transfected with 24 µg 
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of either miR-152b inhibitor expression plasmid or control plasmid and 60 µl of 
Lipofectamine
 TM 2000 (Invitrogen) according to the manufacturer’s protocol. After 
culturing the cells in antibiotic/FBS free medium for 8 h, medium was changed to 
complete medium. After additional 16 h (24 h after the initial transfection), cells were 
harvested for analysis.  
Nuclear extracts (NEs) preparation - After UV treatment, NEs were prepared from 
harvested cells essentially as described (Cevher et al., 2010; Nazeer et al., 2011). Cells 
were lysed by douncing in 4 ml of 10 mM Tris pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 
mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Lysates 
were centrifuged for 10 min at 6000 g, and pellets were resuspended in 20 mM Tris pH 
7.9, 1.5 mM MgCl2, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 
0.3 M NaCl. Preparations were rocked for 30 min at 4°C and centrifuged for 30 min at 
6000 g. Supernatants were quickly frozen and stored at −80°C.  
Fractionation assays - The fractionation of HCT116 cells was performed using 
Subcellular Protein Fractionation kit (Thermo Scientific) following the manufacturer’s 
protocol. Equivalent amounts of cytoplasmic and nuclear component were subjected to 
SDS-PAGE and proteins were detected by immunoblotting using antibodies against Ago-
2 (H-300, Santa Cruz Biotechnology), PARN (kindly provided by Dr. A. Virtanen, 
Uppsala University), Topoisomerase II (H-8, Santa Cruz) and actin (A2066, SIGMA). 
Immunoprecipitation assays – 100 μg of total protein from NEs prepared from different 
cell lines was pre- -A–Sepharose and immunoprecipitated 
with polyclonal antibody against either PARN (H-105 Santa Cruz Biotechnology) or 
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Ago-2 (Santa Cruz Biotechnology) bound to protein A-agarose beads. Antibodies were 
coupled to protein A-agarose beads for 3 h at room temperature in buffer IPP (50 mM 
Tris pH 7.4, 50 mM NaCl and 0.1% Nonidet P-40). Immunoprecipitations were carried 
out for 3 h at 4°C in 200 μl of buffer A (1× phosphate-buffered saline (PBS): 137 mM 
NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.01% Nonidet P-40, 0.5 mM 
PMSF, and 0.04% bovine serum albumin). The beads were recovered by centrifugation 
and treated at 4°C with 50 μg of RNase A/ml for 10 min. Finally, washing was performed 
with buffer A plus increasing amounts of NaCl. Aliquots of pellets and supernatants were 
analyzed by SDS-PAGE and immunoblotting. Results from three independent samples 
were analyzed and quantified using Image J program.   
Purification of recombinant proteins - A plasmid encoding the full-length Ago-2 
(kindly provided by Dr. Novina, Harvard Medical School) was transformed into Rosetta 
cells and GST-fusion proteins were purified by binding to and elution from glutathione–
agarose beads as described in (Wang et al., 2009). The plasmid encoding His-PARN and 
its derivatives were transformed into BL21 cells, His fusion proteins were expressed and 
purified by binding to and elution from Ni-Agarose column (Qiagen) as described 
(Nilsson and Virtanen, 2006).  
Protein-protein interaction assays - 2 μg of GST-Ago-2 or GST was incubated with 
glutathione-agarose beads for 2 h at 4°C in 300 μl final volume of binding buffer (1xPBS, 
0.04% bovine serum albumin, 0.5 mM PMSF, 0.001% NP40). Beads were washed 
extensively six times with binding buffer.  2 μg of His-PARN derivatives (full-length, N-
terminal domain (NTD) and C-terminal domain) were added to the GST-/GST-Ago-2-
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bound beads and incubated for 2 h at 4°C in 300 μl final volume of binding buffer.  The 
beads were washed six times with binding buffer plus 300 mM NaCl, resuspended in 
loading buffer, and proteins were fractionated by 12% SDS-PAGE.  Equivalent amounts 
of pellets and supernatants were analyzed by immunoblotting. 2 μg His-PARN was 
incubated with Ni-Magnetic beads for 2 h at 4°C in 300 μl final volume of binding buffer 
(20 mM HEPES pH 7.9, 0.5 M KCl, 0.5% NP-40, 10% glycerol, 2 mM-mercaptoethanol 
and 2.5 mM imidazole). Beads were washed extensively six times with binding buffer.  2 
μg of GST-Ago-2 was added to the His-PARN-bound beads and incubated for 2 h at 4°C 
in 300 μl final volume of binding buffer.  The beads were washed six times with binding 
buffer plus 400 mM NaCl, resuspended in loading buffer, and proteins were fractionated 
by 9% SDS PAGE.  Equivalent amounts of pellets and supernatants were analyzed by 
immunoblotting 
In vitro deadenylation assays - Conditions for in vitro deadenylation assays were as 
described (Martinez et al., 2001). Deadenylation assays with His-PARN, derivatives of 
PARN and different concentrations of GST-Ago-2 or Flag-nucleolin phospho-variants 
(kindly provided by Dr. Saxena, Brooklyn College) were carried out in reaction mixtures 
containing 25 mM Hepes pH 7, 100 mM NaCl, 0.1 mM EDTA, 1.5 mM MgCl2, 0.5 mM 
DTT, 2.5% polyvinyl alcohol, 10% glycerol, 0.25 U RNasin, and 10 nM 
7
MeGpppG 
capped in vitro transcribed L3(A30) RNA substrate, radioactively labeled by the inclusion 
of 
32
P-α-UTP during in vitro transcription. Incubations were performed at 30°C for 30 
min; the reactions were terminated and analyzed by electrophoresis in 10% 
polyacrylamide/7 M urea gels. Results from independent samples were quantified by 
using image J program. 
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32
P-labelled p53 3’UTR substrate preparation - WT and mutant p53 3’UTRs were 
amplified from luciferase constructs by PCR using a forward primer including a T3 
promoter and a reverse primer with 20 adenines to create poly(A) tail at the 3’ end of the 
transcript (Forward 5’-ATGGATTCAATTAACCCTCACTAAAGGGAACATTCTCCA 
CTTCTTGTTCCCCACTAC-3’ and Reverse 5’-GGATGATCCATAAGCTT(A)20TGG 
GATATAAAAAGGG-3’). The PCR fragments were digested with Hind III to generate 
the poly(A) tail. Then polyadenylated radiolabeled RNA substrates were synthetized by 
in vitro transcription with T3 polymerase as described (Cevher et al., 2010). 
NEs Deadenylation assays - Conditions for NEs deadenylation assays were as described 
(Cevher et al., 2010). Deadenylation assays using equivalent amounts of total proteins 
from NEs from different cell lines with/without UV treatment or siRNA mediated 
knockdown of Ago-2 were carried out in reaction mixtures containing 25 mM Hepes pH 
7, 100 mM NaCl, 0.1 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, 2.5% polyvinyl alcohol, 
10% glycerol, 0.25 U RNasin, and 10 nM 
7
MeGpppG capped in vitro transcribed L3(A30) 
or p53 3’UTR RNA substrate, radioactively labeled by the inclusion of 32P-α-UTP during 
in vitro transcription. Protein concentrations of the NEs were equalized by Bradford 
assays (Bio-Rad) before used in deadenylation reactions. Incubations were performed at 
30°C for 2 h; the reactions were terminated and analyzed by electrophoresis in 10% 
polyacrylamide/7 M urea gels. Results from independent samples were quantified by 
using image J program. 
RNA purification and microarray analysis - Nuclear RNA was purified from HeLa 
cells using the RNeasy kit (Qiagen) following manufacturer’s protocol. The RNA 
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concentrations of the RNA samples obtained under different conditions were equalized. 
Equivalent amounts of purified RNA were used in microarray analysis. The GeneChip 
Human Gene 1.0 ST (Affymetrix) expression array was used.  Microarray data were 
normalized using the Robust Multichip Average (RMA) method. Significant genes 
determined by t-test (P < 0.05) were subsequently subjected to pathway analysis using 
the Ingenuity Pathway Analysis database.  
Analysis of endogenous mRNAs or miRNA abundance by qRT-PCR – Total RNA 
(nuclear or total) was purified from different cell lines using the RNeasy Mini 
Kit(Qiagen) according to the manufacturer’s directions. The RNA concentration of the 
total RNA samples obtained under different conditions was equalized. Equivalent 
random hexamer primers or oligo-d(T) primers and MMLV reverse transcriptase 
(Promega) according to the manufacturer’s protocol.  qPCR was performed using the 
reverse transcriptase products and Taqman master mix (Applied Biosystem). 
Commercially available primers (GAPDH, ACTIN, c-fos, c-myc, TP53, BCL-XL, 
HDAC1 and RB1CC1) were used in the qRT-PCR reactions (Applied Biosystems). 
miRNAs abundance was assessed by qRT-PCR using All-in-One™ miRNA qRT-PCR 
Reagent Kits and Validated Primers (GeneCopoeia). Relative levels were calculated 
using ΔCτ method. 
RNA isolation and qRT-PCR analysis of mRNA half-lives - Control and PARN 
knockdown RKO cells (see above) were treated with Act-D (8 µg/ml) for 30 min before 
the beginning of the time course. Nuclear RNA was purified at different time points and 
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analyzed by qRT-PCR. Total RNA was isolated at different time points using RNeasy 
Mini Kit (QIAGEN) according to the manufacturer’s directions. p53 mRNA abundance 
was assessed at each time point by qRT-PCR and normalized the non-PARN target gene 
actin. 
Constructs of Luciferase Reporter Vectors - Luciferase vector pEZX-MT01 with TP53 
miTarget™ miRNA 3' UTR target clones (product ID: HmiT054283) was purchased 
from GeneCopoeiaTM. Mutations in the miRNA targeting sites, ARE sequence or both 
signals of p53 3’UTR were introduced with the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies) and the following primers 5’-
GGGTCAATTTCCGTTCGCGAATTCTGTTCTGATCTGCTTTTTCTTTGAGACTGG
G -3’ and 5’-CCCAGTCTCAAAGAAAAAGCAGATCAGAACAGAATTCGCGA-
ACGGAAATTGACCC-3’ for ARE sequence replacement, primers 5’- CTGGA-
TCCACCAAGACTTGTTTTATGATTTCTTTTTTCTTTTTT-3’ and 5’-AAAAAAGA-
AAAAAGAAATCATAAAACAAGTCTTGGTGGATCCAG-3’ for miRNA targeting 
sites replacement and primers 5’-CCAAGACTTGTTTTATGCATGTCCGTTCGCG-
AATTCTGCTGTGATCTGCTTTTTCTTTGAGACTGG -3’ and 5’-CCAGTCTCA-
AAGAAAAAGCAGATCACAGCAGAATTCGCGAACGGACATGCATAAAACAAG
TCTTGG -3’ for both signals replacement following the manufacturer’s instructions. 
Plasmids were sequenced to confirm the presence of the mutation. 24 µg of the different 
luciferase constructs were transfected into cells using Lipofectamine
TM
 2000 reagent 
(Invitrogen). 
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Luciferase assay - Cells were co-transfected with 24 µg of different luciferase constructs 
(Lipofectamine TM 2000 reagent, Invitrogen) and either siRNA-targeting PARN or 
control siRNA. 48 h after transfection cells were harvested and dual luciferase assay was 
performed using Luc-pair miR Luciferase kit from GeneCopoeia following 
manufacturer’s instructions.  
RNA immunoprecipitation (RIP) assays - Immunoprecipitation of nuclear RNA-
protein complexes was performed as described (Selth et al., 2011). Briefly, cells were 
treated with 1% formaldehyde, then NEs were prepared followed by sonication. Extracts 
were treated with DNase (TURBO DNA-free Kit, Ambion), and the resulting material 
was immunoprecipitated with antibodies against PARN (H-105) or control rabbit IgG 
(Sigma). Protein-RNA complexes were treated with proteinase K and reversal of cross-
linking. RNA was extracted from the IPs with phenol-chloroform and analyzed by RT-
qPCR assays. 
RT-qPCR Assays - As described before (Cevher et al., 2010; Nazeer et al., 2011), 
equivalent amounts (2 μg) of purified RNA were used as a template to synthesize cDNA 
using random hexamer primers, oligo-d(T) primers, and GoScript Reverse Transcriptase 
(Promega). Relative levels were calculated using the ΔCτ method. 
RNA Pull-down - Biotin-labeled RNAs were in vitro transcribed with the biotin RNA 
labeling mix (Roche) and T7 RNA polymerase (Promega) following manufacturer’s 
instructions. 3 µg of biotinylated RNA treated with RNase free DNase I (Promega) was 
heated to 9 
0
C in RNA structure buffer (10 mM Tris pH7, 0.1 M KCl, 10 mM MgCl2) and 
shifted to room temperature for 20 min for proper folding. Folded RNA was then mixed 
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with 1 mg of NEs in RIP buffer (150 mM KCl, 25 mM Tris pH 7.4, 0.5 mM DTT, 0.5% 
NP40, 1 mM PMSF and protease inhibitor) and incubated at room temperature for 1 h. 60 
µl of washed Streptavidin magnetic beads were added to each reaction and incubated at 
room temperature for another 1 h. Beads were washed 3 times with RIP buffer and eluted 
in SDS buffer and analyzed by immunoblotting. 
RACE-poly(A) test (PAT) assays - Nuclear RNA from RKO cells treated with 
PARN/control siRNA for 48 h (see above) was isolated using Rneasy Mini Kit 
(QIAGEN) according to the manufacturer’s directions. 100 ng of RNA was reverse-
transcribed using oligo (dT)-anchor primer (5’- GGGGATCCGCGGTTTTTTTTTT -3’) 
and GoScript Reverse Transcriptase (Promega). 1 µl of each cDNA was used for PCR 
amplification by GoTaq PCR mix (Promega) using p53 3’UTR specific primer (5’- 
CTGCATTTTCAC-CCCACCCTTCC -3’ located 90 bp upstream of poly(A) site) and 
oligo(dT)-anchor. PCR products were separated in 8% PAGE and the gels were stained 
with 0.2 mg/ml Ethidium Bromide for 20 min as previously described  (Kleiman et al., 
1998).   
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